

Chiral Cobalt(II) Complex Catalyzed Enantioselective Aza-Piancatelli Rearrangement/Diels-Alder Cascade Reaction

Bin Shen, Qianwen He, Shunxi Dong, Xiaohua Liu*, and Xiaoming Feng*

Key Laboratory of Green Chemistry & Technology, Ministry of Education, College of Chemistry, Sichuan University, Chengdu 610064, People's Republic of China


Content

1. General remarks	2
2. General procedure for the synthesis of chiral <i>N,N'</i> -dioxides	2
3. General procedure for the preparation of the racemic products	3
4. Optimization of the asymmetric reaction conditions.....	4
5. Typical procedure for the catalytic asymmetric reactions	7
6. Scale-up version of the asymmetric reaction.....	7
7. The analytical and spectral characterization data of products	8
8. Product derivatizations	36
9. X-ray structure of 3m	39
10. Control experiments	41
11. Copies of NMR spectra.....	45
12. Copies of CD spectra	79
13. References.....	91

1. General remarks

Reactions were carried out with commercially available reagent in dried apparatus. *o*-Xylene was purchased from CHRON CHEMICALS. THF was pretreated under the potassium hydroxide, and then distilled from the sodium benzophenone under nitrogen atmosphere before use. The yield was the purified state by flash chromatography in silica gel. Enantiomeric excesses were determined by HPLC analysis using the corresponding commercial chiral column (chiralcel IB, IF column) as stated in the experimental procedures at 23 °C with the UV detector at 254 nm. Optical rotations were reported as follows: $[\alpha]_D^{25}$ (*c* g/100 mL, in solvent). The melting points of hexahydro-2a,5-epoxy-cyclopenta[*cd*]isindole were determined by OptiMelt. ^1H NMR spectra were recorded on Bruker ASCEND™ 400M (400 MHz). Chemical shifts were reported in ppm from tetramethylsilane with the solvent resonance as the internal standard (CDCl_3 , $\delta = 7.26$). Spectra were reported as follows: chemical shift (δ ppm), multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, hept = heptet, m = multiplet), coupling constants (Hz), integration and assignment. $^{13}\text{C}\{^1\text{H}\}$ NMR spectra were recorded on Bruker ASCEND™ 400M (100 MHz) with complete proton decoupling. Chemical shifts were reported in ppm from tetramethylsilane with the solvent resonance as the internal standard (CDCl_3 , $\delta = 77.0$). $^{19}\text{F}\{^1\text{H}\}$ NMR spectra were recorded on Bruker ASCEND™ 400M (376 MHz) with complete proton decoupling. chemical shifts δ are given relative to CFCl_3 (external reference, $\delta \text{ } ^{19}\text{F}(\text{CFCl}_3) = 0$), HRMS was recorded on a Thermo Q-Exactive Focus (FTMS+c ESI). All the reactions were carried out under an atmosphere of nitrogen in over-dried apparatus. TLC was performed on glass-backed silica plates. 2-Furfuryl carbinol derivatives were prepared according to reported procedure.^[1] *N*-(Furan-2-ylmethyl)aniline derivatives were prepared according to reported procedure.^[2]

2. General procedure for the synthesis of chiral *N,N'*-dioxides




To the solution of *L*-proline **a** (5.76 g, 50 mmol) in 1,4-dioxane (80 mL) was added NaOH (2.20 g, 55 mmol), H₂O (105 mL) at 0 °C. After stirring for 20 min, (Boc)₂O (11.5 mL, 50 mmol) was added. The reaction mixture was stirred at rt and detected by TLC until the reaction was finished. Next, the mixture was washed with 1 M KHSO₄ solution, saturated NaHCO₃ solution, brine, dried over anhydrous Na₂SO₄, concentrated in vacuo, and directly used for the next step (10.75 g, 99% yield).

To solution of **b** (2.15 g, 10 mmol) in CH₂Cl₂ (20 mL) was added Et₃N (1.54 mL, 11 mmol), isobutyl carbonochloridate (1.43 mL, 11 mmol) at 0 °C under stirring. After 30 min, 2,4,6-tricyclohexylaniline^[3] (3.73 g, 11 mmol) was added. The reaction was stirred at rt and detected by TLC. After 12 h, the mixture was washed with 1 M KHSO₄ solution, saturated NaHCO₃ solution, brine, dried over anhydrous Na₂SO₄, concentrated in vacuo, and directly used for the next step.

TFA (10 mL) was added to the solution of the amide **c** (5.36 g, 10 mmol) in CH₂Cl₂ (10 mL) and stirred at rt until reaction was finished (30 min). Then, CH₂Cl₂ (20 mL) was added. The pH value of the mixture was brought into the range of 10–12 by the addition of 2 M NaOH solution. The aqueous phase was extracted with CH₂Cl₂ (3×20 mL). The combined organic phase was washed with brine, dried over anhydrous Na₂SO₄, concentrated and the residue was subjected to column chromatography on silica gel and eluted with EtOAc/petroleum ether (1:1, v/v) to give the white solid **d** (3.60 g, 82% yield).

K₂CO₃ (5.62 g, 41 mmol) and 1,3-dibromopropane (0.42 mL, 4.1 mmol) was added to a solution of **d** (3.60 g, 8.2 mmol) in CH₃CN (10 mL) under stirring. The resulting reaction mixture was refluxed and monitored by TLC (8 h). Then, CH₂Cl₂ (20 mL) was added, the solid was removed by filtration and washed with CH₂Cl₂. The filtrate was concentrated and the residue was subjected to column chromatography on silica gel and eluted with EtOAc/petroleum ether (1:3 and 1:2, v/v) to give the desired product **e** as a white solid (3.02 g, 81% yield).

Finally, *m*-CPBA (1.42 g, 8.3 mmol) was added to the solution of compound **e** (3.02 g, 3.3 mmol) in CH₂Cl₂ (10 mL) at –20 °C, the resulting reaction mixture was stirred at –20 °C for 30 min. the solvent was removed in vacuo, and the residue was subjected to column chromatography on silica gel and eluted with EtOAc/MeOH (1:1, v/v) to provide the desired *N,N'*-dioxide ligand **L-Prch₃** as a white solid (1.21 g, 39% yield). Other *N,N'*-dioxide ligands were prepared by the similar procedure.^[4]



White solid. 130–132 °C; $[\alpha]_D^{19} = -38.1$ (*c* 0.20, CH₂Cl₂), **¹H NMR** (400 MHz, CDCl₃) δ = 12.33 (s, 2H), 6.98 (s, 4H), 3.71 – 3.85 (m, 6H), 3.28 – 3.40 (m, 4H), 2.97 – 3.03 (m, 2H), 2.68 – 2.78 (m, 2H), 2.60 – 2.63 (m, 6H), 2.44 – 2.54 (m, 4H), 2.06 – 2.15 (m, 2H), 1.72 – 1.84 (m, 30H), 1.26 – 1.45 (m, 30H); **¹³C{¹H} NMR** (101 MHz, CDCl₃) δ = 166.4, 147.0, 128.7, 122.5, 68.1, 64.0, 44.8, 39.9, 34.5, 27.9, 27.4, 27.0, 26.2, 26.2, 20.4, 19.6; **HRMS** (FTMS+c ESI): Calcd for C₆₁H₉₂N₄O₄H⁺ [*M*+H⁺] 945.7197, found 945.7194.

3. General procedure for the preparation of the racemic products

An oven-dried reaction tube was charged with 2-furfuryl carbinol **1** (0.10 mmol), *N*-(furan-2-ylmethyl)aniline **2** (0.10 mmol), Co(BF₄)₂·6H₂O (3.4 mg, 0.01 mmol) and *o*-xylene (1.0 mL)

subsequently. The reaction mixture was stirred at 65 °C for 1 h and then subjected to column chromatography on silica gel and eluted with ethyl acetate/petroleum ether (3:1, v/v) to afford the desired racemic product **3** as a white solid.


4. Optimization of the asymmetric reaction conditions

Table S1. Screening of the metal salts^a

Entry	Metal salt	Yield (%) ^b	dr ^c	ee (%) ^d
1	Zn(OTf) ₂	12	> 19:1	31
2	Cu(OTf) ₂	69	> 19:1	0
3	Yb(OTf) ₃	14	> 19:1	0
4	In(OTf) ₃	47	> 19:1	4
5	Dy(OTf) ₃	<10	> 19:1	−3
6	Co(OTf) ₂	10	> 19:1	57
7	Co(BF ₄) ₂ ·6H ₂ O	36	> 19:1	65
8	Co(ClO ₄) ₂ ·6H ₂ O	50	> 19:1	11
9	Co(NTf ₂) ₂	trace	> 19:1	67

^a All reactions were carried out with **1a** (0.10 mmol), **2a** (0.10 mmol) and metal salt/**L-PrPr₂** (1:1.1, 5 mol%) in toluene (1.0 mL) at 80 °C for 15 h. ^b Yield of the isolated products. ^c Determined by ¹H NMR. ^d Determined by HPLC analysis on a chiral stationary phase.

Table S2. Screening of the ligands^a



Entry	ligand	Yield (%) ^b	dr ^c	ee (%) ^d
1	L₃-PrPr₂	36	> 19:1	65
2	L₃-PiPr₂	10	> 19:1	62
3	L₃-PePr₂	48	> 19:1	3
4	L₃-TQtBu	46	> 19:1	3
5	L₂-PrPr₂	39	> 19:1	38
6	L₃-PrMe₂	50	> 19:1	7
7	L₃-PrEt₂	60	> 19:1	8
8	L₃-PrPr₃	14	> 19:1	81
9	L₃-PrPr₂Ad	42	> 19:1	82
10	L₃-PrCH₃	40	> 19:1	83
11 ^e	L₃-PrCH₃	55	> 19:1	83

^a All reactions were carried out with **1a** (0.10 mmol), **2a** (0.10 mmol) and Co(BF₄)₂·6H₂O/ligand (1:1.1, 5 mol%) in toluene (1.0 mL) at 80 °C for 15 h. ^b Yield of the isolated products. ^c Determined by ¹H NMR. ^d Determined by HPLC analysis on a chiral stationary phase. ^e Co(BF₄)₂·6H₂O/**L₃-PrCH₃** (1:1.1, 10 mol%).

Table 3. Screening of the solvents^a

Entry	solvent	Yield (%) ^b	dr ^c	ee (%) ^d
1	CHCl ₂ CHCl ₂	79	> 19:1	25
2	MeNO ₂	65	> 19:1	5
3	<i>o</i> -xylene	63	> 19:1	85
4	<i>m</i> -xylene	58	> 19:1	81
5	<i>p</i> -xylene	73	> 19:1	51
6	mesitylene	37	> 19:1	82
7	bromobenzene	67	> 19:1	55
8	benzotrifluoride	24	> 19:1	77
9	4-methylanisole	48	> 19:1	74
10	toluene	55	> 19:1	83

^a All reactions were carried out with **1a** (0.10 mmol), **2a** (0.10 mmol) and Co(BF₄)₂·6H₂O/**L₃-PrCH₃** (1:1.1, 10 mol%) in solvent (1.0 mL) at 80 °C for 15 h. ^b Yield of the isolated products. ^c Determined by ¹H NMR. ^d Determined by HPLC analysis on a chiral stationary phase.

Table 4. Screening of the reaction concentration^a

Entry	solvent	Yield (%) ^b	dr ^c	ee (%) ^d
1	<i>o</i> -xylene	79	> 19:1	25
2	MeNO ₂	65	> 19:1	5
3	<i>o</i> -xylene	63	> 19:1	85
4	<i>m</i> -xylene	58	> 19:1	81
5	<i>p</i> -xylene	73	> 19:1	51
6	mesitylene	37	> 19:1	82
7	bromobenzene	67	> 19:1	55
8	benzotrifluoride	24	> 19:1	77
9	4-methylanisole	48	> 19:1	74
10	toluene	55	> 19:1	83

Entry	<i>o</i> -xylene [mL]	Yield ^b (%)	dr ^c	ee (%) ^d
1	0.5	35	> 19:1	85
2	1.0	63	> 19:1	85
3	1.5	47	> 19:1	80
4	2.0	36	> 19:1	83

^a All reactions were carried out with **1a** (0.10 mmol), **2a** (0.10 mmol) and Co(BF₄)₂·6H₂O/**L₃-Prch₃** (1:1.1, 10 mol%) in *o*-xylene at 80 °C for 15 h. ^b Yield of the isolated products. ^c Determined by ¹H NMR. ^d Determined by HPLC analysis on a chiral stationary phase.

Table 5. Screening of the temperature^a

Entry	T (°C)	Yield (%) ^b	dr ^c	ee (%) ^d
1	90	62	> 19:1	63
2	80	63	> 19:1	85
3	70	47	> 19:1	87
4	65	20	> 19:1	92
5	60	trace	> 19:1	91

^a All reactions were carried out with **1a** (0.10 mmol), **2a** (0.10 mmol) and Co(BF₄)₂·6H₂O/**L₃-Prch₃** (1:1.1, 10 mol%) in *o*-xylene (1.0 mL). ^b Yield of the isolated products. ^c Determined by ¹H NMR.

^d Determined by HPLC analysis on a chiral stationary phase.


Table 6. Screening of different of 2-furfuryl carbinols^a

 1a: 20 yield, > 19:1 dr, 92% ee	 1b: 88 yield, > 19:1 dr, 90% ee	 1l: 57% yield, > 19:1 dr 70% ee
 1m: NR	 1n: NR	 1o: 32 yield, 39% ee

^a All reactions were carried out with **1** (0.10 mmol), **2a** (0.10 mmol) and Co(BF₄)₂·6H₂O/**L₃-Prch₃** (1:1.1, 10 mol%) in *o*-xylene (1.0 mL) at 65 °C for 16 h. ^b Yield of the isolated products. ^c Determined by ¹H NMR. ^d Determined by HPLC analysis on a chiral stationary phase. ^e The reaction


was carried out at 70 °C.

5. Typical procedure for the catalytic asymmetric reactions



Typical Procedure: To an oven-dried reaction tube under nitrogen atmosphere was added $\text{Co}(\text{BF}_4)_2 \cdot 6\text{H}_2\text{O}$ (3.4 mg, 10 mol%), $\text{L}_3\text{-PrchH}_3$ (10.4 mg, 11 mol%) and THF (0.3 mL). The mixture was stirred at 35 °C for 30 min. Then the solvent was removed in vacuo and dinitrogen atmosphere was introduced. Then furan-2-yl(4-methoxyphenyl)methanol **1b** (20.3 mg, 0.10 mmol), *N*-(furan-2-ylmethyl)aniline **2a** (17.3 mg, 0.10 mmol) and *o*-xylene (1.0 mL) were added subsequently. After completion of the addition, the reaction mixture was stirred at 65 °C for 16 h. The reaction mixture was subjected to column chromatography on silica gel and eluted with ethyl acetate/petroleum ether (3:1, v/v) to afford the desired product **3b** as a white solid (88% yield, 90% ee).


6. Scale-up version of the asymmetric reaction




To an oven-dried reaction tube under nitrogen atmosphere was added $\text{Co}(\text{BF}_4)_2 \cdot 6\text{H}_2\text{O}$ (136.0 mg, 10 mol%), $\text{L}_3\text{-PrchH}_3$ (416.0 mg, 11 mol%) and THF (12 mL). The mixture was stirred at 35 °C overnight. Then the solvent was removed in vacuo and nitrogen atmosphere was introduced. After that, furan-2-yl(4-methoxyphenyl)methanol **1b** (812.0 mg, 4.0 mmol), *N*-(furan-2-ylmethyl)aniline **2a** (692.0 mg, 4.0 mmol) and *o*-xylene (40.0 mL) were added subsequently. After completion of the addition, the reaction mixture was stirred at 65 °C for 26 h. Then the solvent was removed in vacuo and the residue was subjected to column chromatography on silica gel and eluted with ethyl acetate/petroleum ether (3:1, v/v) to afford the desired product **3b** as a white solid (79% yield, 91% ee).

7. The analytical and spectral characterization data of products


(2a*R*,2a'*R*,5*S*,5a*R*,7*S*,7a*R*)-7-(4-Methoxyphenyl)-1-phenyl-1,2,5,5a,7,7a-hexahydro-2a,5-epoxycyclopenta[*cd*]isoindol-6(2a'*H*)-one (3b)



White solid, 132 – 134 °C, 31.6 mg, 88% yield, 90% ee, >19:1 dr for the isolated product. t: 16 h. $[\alpha]_D^{19} = +180.3$ (*c* 0.14, CH₂Cl₂); HPLC (Daicel chiralcel IB, $\lambda = 254$ nm, *n*-hexane/*i*-PrOH 70/30, 1.0 mL/min) $t_{R(\text{major})} = 11.02$ min, $t_{R(\text{minor})} = 26.09$ min; **¹H NMR** (400 MHz, CDCl₃) $\delta = 7.00 - 7.06$ (m, 4H), 6.89 – 6.93 (m, 2H), 6.75 (d, *J* = 6.0 Hz, 1H), 6.62 (t, *J* = 7.2 Hz, 1H), 6.49 (dd, *J* = 1.6 Hz, *J* = 5.6 Hz, 1H), 6.24 (d, *J* = 8.0 Hz, 2H), 5.29 (d, *J* = 1.6 Hz, 1H), 4.35 (dd, *J* = 6.0 Hz, *J* = 8.8 Hz, 1H), 3.96 (dd, *J* = 10.8 Hz, *J* = 89.2 Hz, 2H), 3.84 (s, 3H), 3.09 (dd, *J* = 6.8 Hz, *J* = 8.8 Hz, 1H), 2.76 (d, *J* = 76.8 Hz, 1H); **¹³C{¹H} NMR** (101 MHz, CDCl₃) $\delta = 216.5, 158.7, 146.9, 137.1, 136.3, 131.5, 129.9, 129.1, 116.6, 114.4, 112.2, 96.2, 84.5, 65.6, 65.1, 55.3, 54.1, 52.8, 50.1$; **HRMS** (FTMS+c ESI): Calcd for C₂₃H₂₁NO₃H⁺ [M+H⁺] 360.1594, found 360.1592. **IR** (neat): 2948, 2909, 2833, 1725, 1599, 1505, 1462, 1346, 1299, 1248, 1028, 828, 745, 690 cm⁻¹.




	Retention Time	Area	% Area
1	11.364	9820549	51.71
2	26.989	9171490	48.29




	Retention Time	Area	% Area
1	11.017	1960832	95.22
2	26.091	98428	4.78


(2a*R*,2a'*R*,5*S*,5a*R*,7*S*,7a*R*)-1-(4-Chlorophenyl)-7-phenyl-1,2,5,5a,7,7a-hexahydro-2a,5-epoxycyclopenta[*cd*]isoindol-6(2a'*H*)-one (3c)



White solid, 139 – 141 °C, 15.2 mg, 42% yield, 91% ee, >19:1 dr for the isolated product. t: 73 h. $[\alpha]^{17}_D = +190.9$ (c 0.21, CH₂Cl₂); HPLC (Daicel chiralcel IF, $\lambda = 254$ nm, *n*-hexane/*i*-PrOH 70/30, 1.0 mL/min) $t_{R(\text{major})} = 9.46$ min, $t_{R(\text{minor})} = 18.90$ min; **¹H NMR** (400 MHz, CDCl₃) $\delta = 7.33 - 7.39$ (m, 3H), 7.10 – 7.12 (m, 2H), 6.93 (d, $J = 9.2$ Hz, 2H), 6.75 (d, $J = 5.6$ Hz, 1H), 6.50 (d, $J = 5.6$ Hz, 1H), 6.08 – 6.10 (m, 2H), 5.30 (s, 1H), 4.35 (dd, $J = 6.0$ Hz, $J = 8.8$ Hz, 1H), 3.93 (dd, $J = 10.8$ Hz, $J = 86.0$ Hz, 2H), 3.77 (d, $J = 6.4$ Hz, 1H), 3.12 (dd, $J = 6.8$ Hz, $J = 8.8$ Hz, 1H), 2.78 (d, $J = 6.8$ Hz, 1H); **¹³C{¹H} NMR** (101 MHz, CDCl₃) $\delta = 215.6$, 145.4, 139.3, 137.0, 136.4, 129.1, 128.9, 128.8, 127.5, 121.5, 113.3, 96.2, 84.6, 65.7, 54.3, 53.0, 50.1; **HRMS** (FTMS+c ESI): Calcd for C₂₂H₁₈^{34.9689}ClNO₂H⁺ [M+H⁺] 364.1099, found 364.1096, Calcd for C₂₂H₁₈^{36.9659}ClNO₂H⁺ [M+H⁺] 366.1069, found 366.1065; **IR** (neat): 2924, 2863, 1729, 1594, 1494, 1454, 1353, 1130, 1072, 1009, 865, 804, 748, 696, 617, 503 cm⁻¹.




	Retention Time	Area	% Area
1	9.424	7939806	48.98
2	18.385	8271145	51.02




	Retention Time	Area	% Area
1	9.459	16508983	95.48
2	18.899	781544	4.52


(2a*R*,2a¹*R*,5*S*,5a*R*,7*S*,7a*R*)-1-(4-Chlorophenyl)-7-(p-tolyl)-1,2,5,5a,7,7a-hexahydro-2a,5-epoxycyclopenta[*cd*]isoindol-6(2a¹*H*)-one (3d)



White solid, 82 – 84 °C, 18.9 mg, 50% yield, 94% ee, >19:1 dr for the isolated product. t: 70 h. $[\alpha]^{17}_D = +169.8$ (*c* 0.22, CH₂Cl₂); HPLC (Daicel chiralcel IB, $\lambda = 254$ nm, *n*-hexane/*i*-PrOH 70/30, 1.0 mL/min) $t_{R(\text{major})} = 9.16$ min, $t_{R(\text{minor})} = 16.74$ min; **¹H NMR** (400 MHz, CDCl₃) $\delta = 7.17 - 7.18$ (m, 2H), 6.94 – 7.00 (m, 4H), 6.74 (d, *J* = 6.0 Hz, 1H), 6.49 (dd, *J* = 1.6 Hz, *J* = 5.6 Hz, 1H), 6.12 – 6.14 (m, 2H), 5.92 (d, *J* = 1.2 Hz, 1H), 4.33 (dd, *J* = 6.4 Hz, *J* = 8.8 Hz, 1H), 3.93 (dd, *J* = 11.2 Hz, *J* = 85.6 Hz, 2H), 3.72 (d, *J* = 6.4 Hz, 1H), 3.11 (dd, *J* = 6.8 Hz, *J* = 9.2 Hz, 1H), 2.77 (d, *J* = 6.8 Hz, 1H), 2.37 (s, 3H); **¹³C{¹H} NMR** (101 MHz, CDCl₃) $\delta = 215.9, 145.4, 137.1, 137.0, 136.4, 136.2, 129.8, 128.8, 128.6, 121.4, 113.3, 96.1, 84.6, 65.7, 65.4, 54.2, 53.0, 50.3, 21.2$; **HRMS** (FTMS+c ESI): Calcd for C₂₃H₂₀^{34.9689}ClNO₂H⁺ [*M*+H⁺] 378.1255, found 378.1270, Calcd for C₂₃H₂₀^{36.9659}ClNO₂H⁺ [*M*+H⁺] 380.1226, found 380.1237; **IR** (neat): 2916, 2848, 1730, 1596, 1495, 1459, 1352, 1186, 1149, 887, 811, 769, 691, 661, 506 cm⁻¹.




	Retention Time	Area	% Area
1	9.168	5999386	52.18
2	16.454	5498136	47.82




	Retention Time	Area	% Area
1	9.158	3664170	97.26
2	16.735	103183	2.74


(2a*R*,2a¹*R*,5*S*,5a*R*,7*S*,7a*R*)-1,7-Bis(4-chlorophenyl)-1,2,5,5a,7,7a-hexahydro-2a,5-epoxycyclopenta[*cd*]isoindol-6(2a¹*H*)-one (3e)



White solid, 124 – 126 °C, 19.1 mg, 48% yield, 83% ee, >19:1 dr for the isolated product. t: 73 h. $[\alpha]_D^{20} = +107.7$ (c 0.18, CH₂Cl₂); HPLC (Daicel chiralcel IB, $\lambda = 254$ nm, *n*-hexane/*i*-PrOH 70/30, 1.0 mL/min) $t_{R(\text{major})} = 10.33$ min, $t_{R(\text{minor})} = 16.43$ min; ¹H NMR (400 MHz, CDCl₃) $\delta = 7.35$ (d, $J = 8.4$ Hz, 2H), 7.05 (d, $J = 8.0$ Hz, 2H), 6.97 (d, $J = 8.8$ Hz, 2H), 6.75 (d, $J = 5.6$ Hz, 1H), 6.50 (dd, $J = 1.6$ Hz, $J = 6.0$ Hz, 1H), 6.09 (d, $J = 9.2$ Hz, 2H), 5.29 (d, $J = 1.2$ Hz, 1H), 4.31 (dd, $J = 6.4$ Hz, $J = 9.2$ Hz, 1H), 3.94 (dd, $J = 11.2$ Hz, $J = 84.0$ Hz, 2H), 3.77 (d, $J = 6.4$ Hz, 1H), 3.11 (d, $J = 6.8$ Hz, $J = 9.2$ Hz, 1H), 2.77 (d, $J = 6.4$ Hz, 1H); ¹³C{¹H} NMR (101 MHz, CDCl₃) $\delta = 215.1, 145.2, 137.7, 137.0, 136.4, 133.4, 130.2, 129.3, 128.9, 121.7, 113.2, 96.2, 84.5, 65.4, 65.1, 54.3, 53.0, 50.3$; HRMS (FTMS+c ESI): Calcd for C₂₂H₁₇^{34.9689}Cl₂NO₂H⁺ [M+H⁺] 398.0709, found 398.0721, Calcd for C₂₂H₁₇^{34.9689}Cl^{36.9659}ClNO₂H⁺ [M+H⁺] 400.0680, found 400.0690, Calcd for C₂₀H₁₇^{36.9659}Cl₂NO₂H⁺ [M+H⁺] 402.0650, found 402.0656; IR (neat): 2928, 2856, 2835, 1732, 1597, 1494, 1460, 1144, 1089, 1073, 991, 865, 829, 804, 741, 653, 503 cm⁻¹.




	Retention Time	Area	% Area
1	10.521	2789118	50.20
2	16.779	2766576	49.80




	Retention Time	Area	% Area
1	10.326	8241847	91.74
2	16.433	742306	8.26


(2a*R*,2a'*R*,5*S*,5a*R*,7*S*,7a*R*)-1-(4-Chlorophenyl)-7-(3,4-dimethoxyphenyl)-1,2,5,5a,7,7a-hexahydro-2a,5-epoxycyclopenta[*cd*]isoindol-6(2a'*H*)-one (3f)



White solid, 76 – 78 °C, 28.8 mg, 68% yield, 93% ee, >19:1 dr for the isolated product. t: 65 h. $[\alpha]_D^{16} = +98.0$ (*c* 0.25, CH₂Cl₂); HPLC (Daicel chiralcel IB, $\lambda = 254$ nm, *n*-hexane/*i*-PrOH 70/30, 1.0 mL/min) $t_{R(\text{major})} = 8.37$ min, $t_{R(\text{minor})} = 13.49$ min; **¹H NMR** (400 MHz, CDCl₃) $\delta = 7.12$ (d, *J* = 7.2 Hz, 1H), 6.93 – 6.96 (m, 2H), 6.82 – 6.86 (m, 2H), 6.74 (d, *J* = 5.6 Hz, 1H), 6.49 (dd, *J* = 1.6 Hz, *J* = 5.6 Hz, 1H), 6.12 – 6.17 (m, 2H), 5.29 (d, *J* = 1.6 Hz, 1H), 4.33 (dd, *J* = 6.0 Hz, *J* = 9.2 Hz, 1H), 3.92 (dd, *J* = 10.8 Hz, *J* = 84.8 Hz, 2H), 3.68 (d, *J* = 6.0 Hz, 1H), 3.11 (dd, *J* = 6.8 Hz, *J* = 9.2 Hz, 1H), 2.77 (d, *J* = 6.8 Hz, 1H), 2.27 (s, 3H), 2.25 (s, 3H); **¹³C{¹H} NMR** (101 MHz, CDCl₃) $\delta = 216.2, 145.5, 137.2, 137.0, 136.6, 136.4, 135.7, 130.3, 130.0, 128.8, 126.1, 121.4, 113.4, 96.1, 84.6, 65.7, 65.4, 54.3, 53.0, 50.3, 19.9, 19.5$; **HRMS** (FTMS+c ESI): Calcd for C₂₄H₂₂^{34.9689}ClNO₄H⁺ [M+Na⁺] 446.1130, found 446.1134, Calcd for C₂₄H₂₂^{36.9659}ClNO₄H⁺ [M+Na⁺] 448.1100, found 448.1111; **IR** (neat): 2917, 2854, 1733, 1597, 1497, 1457, 1354, 1144, 1069, 991, 866, 810, 688, 660, 506 cm⁻¹.




	Retention Time	Area	% Area
1	8.004	12708411	52.39
2	12.395	11547871	47.61




	Retention Time	Area	% Area
1	8.366	9213028	96.76
2	13.488	308101	3.24


(2a*R*,2a¹*R*,5*S*,5a*R*,7*S*,7a*R*)-1-(4-Chlorophenyl)-7-(3-methoxyphenyl)-1,2,5,5a,7,7a-hexahydro-2a,5-epoxycyclopenta[*cd*]isoindol-6(2a¹*H*)-one (3g)



White solid, 63 – 65 °C, 22.8 mg, 58% yield, 90% ee, >19:1 dr for the isolated product. t: 140 h. $[\alpha]^{16}_D = +180.3$ (*c* 0.23, CH₂Cl₂); HPLC (Daicel chiralcel IB, $\lambda = 254$ nm, *n*-hexane/*i*-PrOH 70/30, 1.0 mL/min) $t_{R(\text{major})} = 10.56$ min, $t_{R(\text{minor})} = 24.34$ min; ¹H NMR (400 MHz, CDCl₃) $\delta = 7.29$ (t, *J* = 8.0 Hz, 1H), 6.94 – 6.97 (m, 2H), 6.87 (dd, *J* = 2.4 Hz, *J* = 8.0 Hz, 1H), 6.75 (d, *J* = 5.6 Hz, 1H), 6.70 (d, *J* = 7.6 Hz, 1H), 6.63 – 6.64 (m, 1H), 6.49 (dd, *J* = 1.6 Hz, *J* = 6.0 Hz, 1H), 6.12 – 6.14 (m, 2H), 5.30 (d, *J* = 1.2 Hz, 1H), 4.36 (dd, *J* = 2.0 Hz, *J* = 6.0 Hz, 1H), 3.93 (dd, *J* = 10.8 Hz, *J* = 85.6 Hz, 2H), 3.79 (s, 3H), 3.73 (d, *J* = 6.0 Hz, 1H), 3.11 (dd, *J* = 6.8 Hz, *J* = 9.2 Hz, 1H), 2.78 (d, *J* = 6.8 Hz); ¹³C{¹H} NMR (101 MHz, CDCl₃) $\delta = 215.4, 156.0, 145.4, 140.7, 137.0, 136.4, 130.1, 128.8, 121.5, 121.1, 114.7, 113.3, 112.8, 96.2, 84.6, 65.7, 65.6, 55.2, 54.3, 53.0, 50.2$; HRMS (FTMS+c ESI): Calcd for C₂₃H₂₀^{34.9689}ClNO₃H⁺ [M+H⁺] 394.1204, found 394.1205, Calcd for C₂₃H₂₀^{36.9659}ClNO₃H⁺ [M+H⁺] 396.1175, found 396.1174; IR (neat): 2913, 2839, 1733, 1597, 1495, 1459, 1354, 1244, 1142, 1039, 991, 867, 810, 766, 689, 660, 507 cm⁻¹.




	Retention Time	Area	% Area
1	10.638	61437860	51.30
2	23.542	58317258	48.70




	Retention Time	Area	% Area
1	10.554	18724762	95.18
2	24.368	948184	4.82


(2a*R*,2a'*R*,5*S*,5a*R*,7*S*,7a*R*)-1-(4-Chlorophenyl)-7-(2-methoxyphenyl)-1,2,5,5a,7,7a-hexahydro-2a,5-epoxycyclopenta[*cd*]isoindol-6(2a'*H*)-one (3h)



White solid, 117 – 120 °C, 31.1 mg, 79% yield, 93% ee, >19:1 dr for the isolated product. t: 64 h. $[\alpha]_D^{19} = +198.4$ (*c* 0.31, CH₂Cl₂); HPLC (Daicel chiralcel IB, $\lambda = 254$ nm, *n*-hexane/*i*-PrOH 70/30, 1.0 mL/min) $t_{R(\text{major})} = 8.04$ min, $t_{R(\text{minor})} = 10.54$ min; **¹H NMR** (400 MHz, CDCl₃) $\delta = 7.29 - 7.34$ (m, 1H), 7.12 – 7.14 (m, 1H), 6.92 – 6.98 (m, 4H), 6.73 (d, *J* = 5.6 Hz, 1H), 6.48 – 6.50 (m, 1H), 6.20 – 6.22 (m, 2H), 5.28 (d, *J* = 1.6 Hz, 1H), 4.29 (dd, *J* = 5.2 Hz, *J* = 9.2 Hz, 1H), 3.88 (dd, *J* = 10.4 Hz, *J* = 102.0 Hz, 2H), 3.76 (s, 3H), 3.55 (d, *J* = 2.8 Hz, 1H), 3.11 (dd, *J* = 6.8 Hz, *J* = 8.8 Hz, 1H), 2.82 (d, *J* = 6.8 Hz, 1H); **¹³C{¹H} NMR** (101 MHz, CDCl₃) $\delta = 216.7, 155.6, 145.6, 136.9, 136.3, 132.5, 129.6, 129.1, 128.8, 121.2, 121.2, 113.1, 111.3, 95.8, 84.6, 64.9, 55.3, 54.4, 53.6, 50.3$; **HRMS** (FTMS+c ESI): Calcd for C₂₃H₂₀^{34.9689}ClNO₃H⁺ [M+H⁺] 394.1204, found 394.1203, Calcd for C₂₃H₂₀^{36.9659}ClNO₃H⁺ [M+H⁺] 396.1175, found 396.1172; **IR** (neat): 2936, 2916, 2857, 2840, 1731, 1593, 1493, 1458, 1350, 1270, 1147, 1025, 992, 866, 757, 729, 700 cm⁻¹.




	Retention Time	Area	% Area
1	8.357	46223035	49.49
2	10.779	47179866	50.51




	Retention Time	Area	% Area
1	8.039	1479828	96.77
2	10.541	49397	3.23


(2a*R*,2a'*1R*,5*S*,5a*R*,7*S*,7a*R*)-7-(Benzo[*d*][1,3]dioxol-5-yl)-1-(4-chlorophenyl)-1,2,5,5a,7,7a-hexahydro-2a,5-epoxycyclopenta[*cd*]isoindol-6(2a'*1H*)-one (3i)



White solid, 84 – 86 °C, 27.7 mg, 68% yield, 91% ee, >19:1 dr for the isolated product. t: 65 h. $[\alpha]_D^{16} = +112.2$ (*c* 0.34, CH₂Cl₂); HPLC (Daicel chiralcel IB, $\lambda = 254$ nm, *n*-hexane/*i*-PrOH 70/30, 1.0 mL/min) $t_{R(\text{major})} = 14.28$ min, $t_{R(\text{minor})} = 28.20$ min; ¹H NMR (400 MHz, CDCl₃) $\delta = 6.97 - 7.01$ (m, 2H) 6.79 – 6.81 (m, 1H), 6.73 – 6.75 (m, 1H), 6.57 – 6.59 (m, 2H), 6.49 (dd, *J* = 1.6 Hz, *J* = 5.6 Hz, 1H), 6.15 – 6.19 (m, 2H), 5.99 (d, *J* = 4.4 Hz, 2H), 5.28 (d, *J* = 1.2 Hz, 1H), 4.29 (dd, *J* = 6.4 Hz, *J* = 9.6 Hz, 1H), 3.92 (dd, *J* = 11.2 Hz, *J* = 84.0 Hz, 2H), 3.69 (d, *J* = 6.0 Hz, 1H), 3.09 (dd, *J* = 6.8 Hz, *J* = 9.2 Hz, 1H), 2.75 (d, *J* = 6.8 Hz, 1H); ¹³C{¹H} NMR (101 MHz, CDCl₃) $\delta = 215.7, 148.2, 146.9, 145.4, 136.9, 136.3, 132.8, 128.9, 122.5, 121.5, 113.3, 108.8, 96.1, 84.5, 65.6, 65.4, 54.1, 52.8, 50.3$; HRMS (FTMS+c ESI): Calcd for C₂₃H₁₈^{34.9689}ClNO₄H⁺ [M+H⁺] 408.0997, found 408.1013, Calcd for C₂₃H₁₈^{36.9659}ClNO₄H⁺ [M+H⁺] 410.0968, found 410.0983; IR (neat): 2901, 2853, 1732, 1597, 1495, 1441, 1354, 1240, 1143, 1035, 928, 867, 808, 660, 506 cm⁻¹.




	Retention Time	Area	% Area
1	14.311	9970009	51.48
2	27.310	9396462	48.52




	Retention Time	Area	% Area
1	14.277	15119753	95.76
2	28.195	669792	4.24


(2a*R*,2a'*R*,5*S*,5a*R*,7*S*,7a*R*)-1-(4-Chlorophenyl)-7-(naphthalen-2-yl)-1,2,5,5a,7,7a-hexahydro-2a,5-epoxycyclopenta[*cd*]isoindol-6(2a'*H*)-one (3j)



White solid, 148 – 150 °C, 13.6 mg, 31% yield, 94% ee, >19:1 dr for the isolated product. t: 71 h. $[\alpha]_D^{25} = +132.8$ (c 0.13, CH₂Cl₂); HPLC (Daicel chiralcel IB, $\lambda = 254$ nm, *n*-hexane/*i*-PrOH 70/30, 1.0 mL/min) $t_{R(\text{major})} = 11.74$ min, $t_{R(\text{minor})} = 28.69$ min; ¹H NMR (400 MHz, CDCl₃) $\delta = 7.85 - 7.88$ (m, 2H), 7.76 – 7.79 (m, 1H), 7.60 (s, 1H), 7.47 – 7.52 (m, 2H), 7.21 (dd, $J = 2.0$ Hz, $J = 8.4$ Hz, 1H), 6.84 – 6.88 (m, 2H), 6.77 (d, $J = 6.0$ Hz, 1H), 6.52 (dd, $J = 1.6$ Hz, $J = 5.6$ Hz, 1H), 5.33 (d, $J = 1.6$ Hz, 1H), 4.49 (dd, $J = 6.0$ Hz, $J = 9.2$ Hz, 1H), 3.96 (dd, $J = 11.2$ Hz, $J = 90.0$ Hz, 2H), 3.94 (d, $J = 6.0$ Hz, 1H), 3.19 (dd, $J = 6.8$ Hz, $J = 8.8$ Hz, 1H), 2.84 (d, $J = 6.8$ Hz, 1H); ¹³C{¹H} NMR (101 MHz, CDCl₃) $\delta = 215.7, 145.4, 137.0, 136.6, 136.4, 133.6, 132.6, 129.0, 128.9, 128.1, 127.8, 127.7, 126.4, 126.4, 126.0, 121.5, 113.3, 96.2, 84.7, 65.9, 65.6, 54.4, 53.2, 50.3$; HRMS (FTMS+c ESI): Calcd for C₂₆H₂₀^{34.9689}ClNO₂H⁺ [M+H⁺] 414.1255, found 414.1266, Calcd for C₂₆H₂₀^{36.9659}ClNO₂H⁺ [M+H⁺] 416.1226, found 416.1236; IR (neat): 2907, 2847, 1736, 1596, 1495, 1459, 1354, 1269, 1148, 1125, 861, 805, 746, 685, 654, 506, 475 cm⁻¹.




	Retention Time	Area	% Area
1	11.718	23990487	49.67
2	27.907	24311296	50.33




	Retention Time	Area	% Area
1	11.739	35109544	97.07
2	28.691	1060800	2.93


(2a*R*,2a'*R*,5*S*,5a*R*,7*S*,7a*R*)-1-(4-Chlorophenyl)-7-(thiophen-2-yl)-1,2,5,5a,7,7a-hexahydro-2a,5-epoxycyclopenta[*cd*]isoindol-6(2a'*H*)-one (3k)



White solid, 124 – 126 °C, 22.5 mg, 61% yield, 87% ee, >19:1 dr for the isolated product. t: 22 h. $[\alpha]^{16}_D = +167.6$ (c 0.24, CH₂Cl₂); HPLC (Daicel chiralcel IF, $\lambda = 254$ nm, *n*-hexane/*i*-PrOH 70/30, 1.0 mL/min) $t_{R(\text{major})} = 21.35$ min, $t_{R(\text{minor})} = 50.91$ min; ¹H NMR (400 MHz, CDCl₃) $\delta = 7.30$ (d, $J = 2.8$ Hz, 1H), 6.99 – 7.04 (m, 3H), 6.89 – 6.90 (m, 1H), 6.74 (d, $J = 6.0$ Hz, 1H), 6.50 (dd, $J = 1.6$ Hz, $J = 5.6$ Hz, 1H), 6.23 (d, $J = 8.8$ Hz, 2H), 5.28 (d, $J = 1.2$ Hz, 1H), 4.36 (dd, $J = 6.4$ Hz, $J = 9.2$ Hz, 1H), 4.11 (d, $J = 6.0$ Hz, 1H), 3.93 (dd, $J = 11.2$ Hz, $J = 81.2$ Hz, 2H), 3.09 (dd, $J = 6.8$ Hz, $J = 9.2$ Hz, 1H), 2.77 (d, $J = 6.8$ Hz, 1H); ¹³C{¹H} NMR (101 MHz, CDCl₃) $\delta = 212.6$, 150.5, 145.4, 142.4, 136.9, 136.4, 128.9, 121.7, 112.8, 110.8, 109.6, 96.2, 84.5, 61.8, 58.5, 53.7, 52.6, 50.1; HRMS (FTMS+c ESI): Calcd for C₂₀H₁₆^{34.9689}ClNO₂SH⁺ [M+H⁺] 370.0663, found 370.0666, Calcd for C₂₀H₁₆^{36.9659}ClNO₂SH⁺ [M+H⁺] 372.0634, found 372.0632; IR (neat): 2922, 2858, 1730, 1594, 1494, 1355, 1328, 1308, 1150, 1069, 866, 802, 687, 651, 501 cm⁻¹.




	Retention Time	Area	% Area
1	22.400	16358400	50.53
2	53.118	16014838	49.47




	Retention Time	Area	% Area
1	21.351	3544669	93.51
2	50.913	245905	6.49


(2a*R*,2a'*R*,5*S*,5a*R*,7*R*,7a*R*)-1-(4-Chlorophenyl)-7-(furan-2-yl)-1,2,5,5a,7,7a-hexahydro-2a,5-epoxycyclopenta[*cd*]isoindol-6(2a'*H*)-one (3I)



White solid, 124 – 126 °C, 18.0 mg, 51% yield, 91% ee, >19:1 dr for the isolated product. t: 22 h. $[\alpha]^{16}_D = +149.4$ (*c* 0.18, CH₂Cl₂); HPLC (Daicel chiralcel IF, $\lambda = 254$ nm, *n*-hexane/*i*-PrOH 70/30, 1.0 mL/min) $t_{R(\text{major})} = 14.78$ min, $t_{R(\text{minor})} = 30.87$ min; **¹H NMR** (400 MHz, CDCl₃) $\delta = 7.45$ (d, *J* = 0.8 Hz, 1H), 7.03 (d, *J* = 8.8 Hz, 2H), 6.73 (d, *J* = 6.0 Hz, 1H), 6.49 (dd, *J* = 1.6 Hz, *J* = 5.6 Hz, 1H), 6.40 – 6.41 (m, 1H), 6.23 (d, *J* = 3.2 Hz, 1H), 6.19 (d, *J* = 9.2 Hz, 2H), 5.26 (d, *J* = 1.2 Hz, 1H), 4.56 (dd, *J* = 6.8 Hz, *J* = 9.2 Hz, 1H), 3.92 (d, *J* = 6.8 Hz, 1H), 3.91 (dd, *J* = 11.2 Hz, *J* = 68.0 Hz, 2H), 3.09 (dd, *J* = 6.8 Hz, *J* = 9.2 Hz, 1H), 2.75 (d, *J* = 6.8 Hz, 1H); **¹³C{¹H} NMR** (101 MHz, CDCl₃) $\delta = 212.6, 150.5, 145.4, 142.4, 136.9, 136.4, 128.9, 121.7, 112.8, 110.8, 109.6, 96.2, 84.5, 61.8, 58.5, 53.7, 52.6, 50.1$; **HRMS** (FTMS+c ESI): Calcd for C₂₀H₁₆^{34.9689}ClNO₃H⁺ [M+H⁺] 354.0891, found 354.0895, Calcd for C₂₀H₁₆^{36.9659}ClNO₃H⁺ [M+H⁺] 356.0862, found 356.0862; **IR** (neat): 2919, 2855, 1732, 1699, 1594, 1495, 1458, 1355, 1337, 1308, 1150, 1067, 1010, 868, 806, 739, 691, 657, 508 cm⁻¹.




	Retention Time	Area	% Area
1	15.853	8375252	50.90
2	32.366	8078781	49.10




	Retention Time	Area	% Area
1	14.773	5261915	95.34
2	30.870	256915	4.66


(2aR,2a¹R,5S,5aR,7S,7aR)-1-(4-Bromophenyl)-7-phenyl-1,2,5,5a,7,7a-hexahydro-2a,5-epoxycyclopenta[cd]isoindol-6(2a¹H)-one (3m)



White solid, 158 – 160 °C, 13.8 mg, 34% yield, 94% ee, >19:1 dr for the isolated product. t: 72 h. $[\alpha]^{20}_D = +174.5$ (c 0.11, CH₂Cl₂); HPLC (Daicel chiralcel IB, $\lambda = 254$ nm, *n*-hexane/*i*-PrOH 70/30, 1.0 mL/min) $t_{R(\text{major})} = 9.73$ min, $t_{R(\text{minor})} = 19.56$ min; ¹H NMR (400 MHz, CDCl₃) $\delta = 7.33 - 7.39$ (m, 3H), 7.10 (d, *J* = 6.8 Hz, 2H), 7.06 (d, *J* = 8.8 Hz, 2H), 6.75 (d, *J* = 6.0 Hz, 1H), 6.49 – 6.51 (m, 1H), 6.05 (d, *J* = 8.8 Hz, 2H), 5.30 (s, 1H), 4.34 (dd, *J* = 6.4 Hz, *J* = 9.2 Hz, 1H), 3.93 (dd, *J* = 11.2 Hz, *J* = 86.4 Hz, 2H), 3.77 (d, *J* = 6.0 Hz, 1H), 3.12 (dd, *J* = 6.8 Hz, *J* = 8.8 Hz, 1H), 2.78 (d, *J* = 6.8 Hz, 1H); ¹³C{¹H} NMR (101 MHz, CDCl₃) $\delta = 215.5$, 145.7, 139.3, 137.0, 136.4, 131.7, 129.1, 128.8, 127.5, 113.9, 108.6, 96.1, 84.6, 65.7, 54.3, 53.0, 50.2; HRMS (FTMS+c ESI): Calcd for C₂₂H₁₈^{78.9183}BrNO₂H⁺ [M+H⁺] 408.0594, found 408.0594; Calcd for C₂₂H₁₈^{80.9163}BrNO₂H⁺ [M+H⁺] 410.0573, found 410.0573; IR (neat): 2999, 2921, 2849, 1733, 1586, 1493, 1452, 1351, 1260, 1138, 1072, 990, 858, 805, 742, 695, 645, 618, 545, 503 cm⁻¹.




	Retention Time	Area	% Area
1	9.715	14969108	51.94
2	19.006	13852798	48.06




	Retention Time	Area	% Area
1	9.730	10524290	96.95
2	19.556	330595	3.05


(2a*R*,2a¹*R*,5*S*,5a*R*,7*S*,7a*R*)-1-(3-Chlorophenyl)-7-(4-methoxyphenyl)-1,2,5,5a,7,7a-hexahydro-2a,5-epoxycyclopenta[*cd*]isoindol-6(2a¹*H*)-one (3n)



White solid, 141 – 143 °C, 25.2 mg, 64% yield, 90% ee, >19:1 dr for the isolated product. t: 22h. $[\alpha]_D^{20} = +188.3$ (*c* 0.32, CH₂Cl₂); HPLC (Daicel chiralcel IB, $\lambda = 254$ nm, *n*-hexane/*i*-PrOH 70/30, 1.0 mL/min) $t_{R(\text{major})} = 13.42$ min, $t_{R(\text{minor})} = 34.03$ min; ¹H NMR (400 MHz, CDCl₃) $\delta = 7.02 - 7.05$ (m, 2H), 6.89 – 6.93 (m, 3H), 6.74 (d, *J* = 5.6 Hz, 1H), 6.58 (dd, *J* = 1.6 Hz, *J* = 8.0 Hz, 1H), 6.49 (dd, *J* = 1.6 Hz, *J* = 5.6 Hz, 1H), 6.17 (t, *J* = 2.4 Hz, 1H), 6.09 (dd, *J* = 2.4 Hz, *J* = 8.0 Hz, 1H), 5.28 (d, *J* = 1.6 Hz, 1H), 4.31 (dd, *J* = 6.4 Hz, *J* = 9.2 Hz, 1H), 3.94 (dd, *J* = 10.8 Hz, *J* = 77.2 Hz, 2H), 3.83 (s, 3H), 3.73 (d, *J* = 6.0 Hz, 1H), 3.08 (dd, *J* = 2.8 Hz, *J* = 6.8 Hz, 1H), 2.76 (d, *J* = 6.8 Hz, 1H); ¹³C{¹H} NMR (101 MHz, CDCl₃) $\delta = 216.0, 159.0, 147.8, 136.9, 136.4, 134.9, 131.3, 129.9, 129.9, 116.4, 114.6, 112.5, 110.4, 96.0, 84.5, 65.8, 64.8, 53.3, 54.1, 52.7, 50.1$; HRMS (FTMS+c ESI): Calcd for C₂₃H₂₀^{34.9689}ClNO₃H⁺ [M+H⁺] 394.1204, found 394.1214, Calcd for C₂₃H₂₀^{36.9659}ClNO₃H⁺ [M+H⁺] 396.1175, found 396.1183; IR (neat): 2932, 2910, 2836, 1729, 1590, 1491, 1462, 1362, 1246, 1141, 985, 825, 752, 691 cm⁻¹.




	Retention Time	Area	% Area
1	13.127	11370339	50.82
2	32.415	11001240	49.18




	Retention Time	Area	% Area
1	13.422	1496139	95.04
2	34.026	78104	4.96


(2a*R*,2a¹*R*,5*S*,5a*R*,7*S*,7a*R*)-7-(4-Methoxyphenyl)-1-(*m*-tolyl)-1,2,5,5a,7,7a-hexahydro-2a,5-epoxycyclopenta[*cd*]isoindol-6(2a¹*H*)-one (3o)



White solid, 125 – 127 °C, 28.0 mg, 75% yield, 89% ee, >19:1 dr for the isolated product. t: 20 h. $[\alpha]_D^{19} = +166.3$ (c 0.25, CH₂Cl₂); HPLC (Daicel chiralcel IB, $\lambda = 254$ nm, *n*-hexane/*i*-PrOH 70/30, 1.0 mL/min) $t_{R(\text{major})} = 10.81$ min, $t_{R(\text{minor})} = 25.68$ min; **¹H NMR** (400 MHz, CDCl₃) $\delta = 7.04 - 7.07$ (m, 2H), 6.91 – 6.98 (m, 3H), 6.74 (d, $J = 5.6$ Hz, 1H), 6.48 (dd, $J = 1.6$ Hz, $J = 5.6$ Hz, 1H), 6.45 (d, $J = 7.6$ Hz, 1H), 6.12 (dd, $J = 2.4$ Hz, $J = 8.4$ Hz, 1H), 5.95 (s, 1H), 4.33 (dd, $J = 6.4$ Hz, $J = 9.2$ Hz, 1H), 3.95 (dd, $J = 11.2$ Hz, $J = 81.2$ Hz, 2H), 3.84 (s, 3H), 3.76 (d, $J = 6.4$ Hz, 1H), 3.06 (dd, $J = 6.8$ Hz, $J = 8.8$ Hz, 1H), 2.75 (d, $J = 6.8$ Hz, 1H), 2.01 (s, 3H); **¹³C{¹H} NMR** (101 MHz, CDCl₃) $\delta = 216.6, 158.8, 146.9, 138.8, 137.1, 136.2, 130.0, 129.0, 117.4, 114.4, 113.6, 109.1, 96.2, 84.4, 65.8, 65.2, 55.3, 54.2, 52.7, 50.0, 21.5$; **HRMS** (FTMS+c ESI): Calcd for C₂₄H₂₃NO₃H⁺ [M+H⁺] 374.1751, found 374.1754; **IR** (neat): 2955, 2910, 2855, 2837, 1726, 1602, 1579, 1504, 1459, 1356, 1301, 1242, 1174, 1145, 1028, 866, 827, 764, 689, 587 cm⁻¹.




	Retention Time	Area	% Area
1	11.166	10291893	52.79
2	26.125	9204462	47.21




	Retention Time	Area	% Area
1	10.808	56438170	94.30
2	25.683	3413739	5.70


(2a*R*,2a'*R*,5*S*,5a*R*,7*S*,7a*R*)-1-(3,5-Di-*tert*-butylphenyl)-7-(4-methoxyphenyl)-1,2,5,5a,7,7a-hexahydro-2a,5-epoxycyclopenta[*cd*]isoindol-6(2a'*H*)-one (3p)



White solid, 164 – 166 °C, 31.1 mg, 66% yield, 90% ee, >19:1 dr for the isolated product. t: 21 h. $[\alpha]_D^{19} = +117.0$ (*c* 0.19, CH₂Cl₂); HPLC (Daicel chiralcel IB, $\lambda = 254$ nm, *n*-hexane/*i*-PrOH 70/30, 1.0 mL/min) $t_{R(\text{major})} = 6.09$ min, $t_{R(\text{minor})} = 13.61$ min; **¹H NMR** (400 MHz, CDCl₃) $\delta = 7.10 - 7.12$ (m, 2H), 6.92 – 6.94 (m, 2H), 6.75 – 6.76 (m, 2H), 6.48 (dd, *J* = 1.6 Hz, *J* = 5.6 Hz, 1H), 6.22 (d, *J* = 1.2 Hz, 1H), 5.03 (d, *J* = 1.2 Hz, 1H), 4.55 (dd, *J* = 6.4 Hz, *J* = 9.2 Hz, 1H), 4.01 (dd, *J* = 10.8 Hz, *J* = 84.0 Hz, 2H), 3.78 – 3.82 (m, 4H), 3.07 (dd, *J* = 6.8 Hz, *J* = 8.8 Hz, 1H), 2.74 (d, *J* = 8.4 Hz, 1H), 1.11 (s, 18H); **¹³C{¹H} NMR** (101 MHz, CDCl₃) $\delta = 216.7, 158.9, 151.7, 146.7, 137.2, 136.2, 131.4, 129.8, 114.9, 111.6, 107.0, 96.2, 84.7, 65.7, 65.3, 55.3, 54.0, 52.8, 50.4, 34.7, 31.2$; **HRMS** (FTMS+c ESI): Calcd for C₃₁H₃₇NO₃H⁺ [M+H⁺] 472.2864, found 472.2864; **IR** (neat): 2961, 2926, 2865, 1726, 1590, 1511, 1437, 1341, 1245, 1177, 1128, 1024, 870, 848, 751, 732, 685, 590 cm⁻¹.




	Retention Time	Area	% Area
1	6.265	7046031	51.84
2	14.084	6544934	48.16




	Retention Time	Area	% Area
1	6.087	36208047	94.82
2	13.613	1979134	5.18

(2a*R*,2a'*R*,5*S*,5a*R*,7*S*,7a*R*)-7-(4-Methoxyphenyl)-1-(3-(trifluoromethyl)phenyl)-1,2,5,5a,7,7a-hexahydro-2a,5-epoxycyclopenta[*cd*]isoindol-6(2a'*H*)-one (3q)




3q

White solid, 76 – 78 °C, 32.9 mg, 77% yield, 92% ee, >19:1 dr for the isolated product. t: 29 h. $[\alpha]_D^{19} = +150.5$ (c 0.20, CH₂Cl₂); HPLC (Daicel chiralcel IB, $\lambda = 254$ nm, *n*-hexane/*i*-PrOH 70/30, 1.0 mL/min) $t_{R(\text{major})} = 10.69$ min, $t_{R(\text{minor})} = 27.50$ min; **¹H NMR** (400 MHz, CDCl₃) $\delta = 7.12$ (t, $J = 8.0$ Hz, 1H), 7.02 – 7.04 (m, 2H), 6.91 – 6.93 (m, 2H), 6.83 – 6.85 (m, 1H), 6.74 – 6.76 (m, 1H), 6.50 – 6.51 (m, 1H), 6.38 – 6.42 (m, 2H), 5.30 (s, 1H), 4.37 (dd, $J = 6.4$ Hz, $J = 8.8$ Hz, 1H), 3.99 (dd, $J = 11.2$ Hz, $J = 82.0$ Hz, 2H), 3.83 (s, 3H), 3.75 (d, $J = 6.4$ Hz, 1H), 3.11 (dd, $J = 6.8$ Hz, $J = 8.8$ Hz, 1H), 2.78 (d, $J = 6.8$ Hz, 1H); **¹³C{¹H} NMR** (101 MHz, CDCl₃) $\delta = 215.8, 159.1, 146.9, 136.8, 136.4, 131.4$ (d, $J = 31.7$ Hz, 1C), 131.0, 129.9, 129.4, 124.4 (q, $J = 272.0$ Hz, 1C), 115.0, 114.7, 123.0 (q, $J = 3.7$ Hz, 1C), 108.9 (q, $J = 4.2$ Hz, 1C), 96.0, 84.5, 65.8, 64.8, 55.3, 54.1, 52.7, 50.2; **¹⁹F{¹H} NMR** (376 MHz, CDCl₃) $\delta = -63.0$; **HRMS** (FTMS+c ESI): Calcd for C₂₄H₂₀F₃NO₃H⁺ [M+H⁺] 428.1468, found 428.1474; **IR** (neat): 2918, 2844, 1732, 1610, 1509, 1456, 1366, 1252, 1160, 1115, 1072, 1031, 1001, 860, 832, 759, 691 cm⁻¹.




	Retention Time	Area	% Area
1	10.792	4174782	51.36
2	27.083	3953573	48.64




	Retention Time	Area	% Area
1	10.692	32360477	96.06
2	27.505	1327752	3.94


(2a*R*,2a'*R*,5*S*,5a*R*,7*S*,7a*R*)-1-(4-Chlorophenyl)-7-(4-methoxyphenyl)-1,2,5,5a,7,7a-hexahydro-2a,5-epoxycyclopenta[*cd*]isoindol-6(2a'*H*)-one (3r)



White solid, 145 – 147 °C, 31.1 mg, 79% yield, 93% ee, >19:1 dr for the isolated product. t: 16h. $[\alpha]_D^{19} = +157.1$ (*c* 0.29, CH₂Cl₂); HPLC (Daicel chiralcel IB, $\lambda = 254$ nm, *n*-hexane/*i*-PrOH 70/30, 1.0 mL/min) $t_{R(\text{major})} = 12.86$ min, $t_{R(\text{minor})} = 33.26$ min; **¹H NMR** (400 MHz, CDCl₃) $\delta = 7.01 - 7.04$ (m, 2H), 6.94 – 6.97 (m, 2H), 6.90 – 6.92 (m, 2H), 6.74 (d, *J* = 6.0 Hz, 1H), 6.49 (dd, *J* = 1.6 Hz, *J* = 6.0 Hz, 1H), 6.13 (d, *J* = 8.8 Hz, 2H), 5.29 (d, *J* = 1.2 Hz, 1H), 4.30 (dd, *J* = 6.4 Hz, *J* = 9.2 Hz, 1H), 3.80 – 4.04 (m, 2H), 3.83 (s, 3H), 3.72 (d, *J* = 6.0 Hz, 1H), 3.09 (dd, *J* = 6.8 Hz, *J* = 8.8 Hz, 1H), 2.76 (d, *J* = 6.8 Hz, 1H); **¹³C{¹H} NMR** (101 MHz, CDCl₃) $\delta = 216.1, 158.8, 145.4, 136.9, 136.4, 131.3, 129.9, 128.8, 121.4, 114.5, 113.3, 96.1, 84.5, 65.7, 64.9, 55.3, 54.1, 52.8, 50.2$; **HRMS** (FTMS+c ESI): Calcd for C₂₃H₂₀^{34.9689}ClNO₃H⁺ [M+H⁺] 394.1204, found 394.1208, Calcd for C₂₃H₂₀^{36.9659}ClNO₃H⁺ [M+H⁺] 396.1175, found 396.1177; **IR** (neat): 2906, 2840, 1735, 1598, 1497, 1463, 1352, 1247, 1180, 1150, 1126, 1026, 867, 828, 805, 656, 544, 509 cm⁻¹.




	Retention Time	Area	% Area
1	12.779	8809260	51.45
2	32.462	8311806	48.55




	Retention Time	Area	% Area
1	12.856	5344764	96.56
2	33.263	190321	3.44


(2a*R*,2a'*R*,5*S*,5a*R*,7*S*,7a*R*)-1-(4-Bromophenyl)-7-(4-methoxyphenyl)-1,2,5,5a,7,7a-hexahydro-2a,5-epoxycyclopenta[*cd*]isoindol-6(2a'*H*)-one (3s)



White solid, 146 – 148 °C, 31.0 mg, 71% yield, 93% ee, >19:1 dr for the isolated product. t: 25 h. $[\alpha]_D^{19} = +139.3$ (c 0.42, CH₂Cl₂); HPLC (Daicel chiralcel IB, $\lambda = 254$ nm, *n*-hexane/*i*-PrOH 70/30, 1.0 mL/min) $t_{R(\text{major})} = 13.21$ min, $t_{R(\text{minor})} = 33.43$ min; **¹H NMR** (400 MHz, CDCl₃) $\delta = 7.07 - 7.10$ (m, 2H), 7.01 – 7.03 (m, 2H), 6.89 – 6.92 (m, 2H), 6.74 (d, $J = 6.0$ Hz, 1H), 6.49 (dd, $J = 2.0$ Hz, $J = 4.0$ Hz, 1H), 6.09 (d, $J = 8.8$ Hz, 2H), 5.28 (d, $J = 1.6$ Hz, 1H), 4.29 (dd, $J = 6.4$ Hz, $J = 9.2$ Hz, 1H), 3.91 (dd, $J = 10.8$ Hz, $J = 84.8$ Hz, 2H), 3.83 (s, 3H), 3.09 (dd, $J = 6.8$ Hz, $J = 9.2$ Hz, 1H), 2.75 (d, $J = 7.6$ Hz, 1H); **¹³C{¹H} NMR** (101 MHz, CDCl₃) $\delta = 216.0, 158.8, 145.8, 136.9, 136.4, 131.7, 131.2, 129.8, 114.5, 113.9, 108.5, 96.1, 84.5, 65.7, 64.8, 55.2, 54.1, 52.8, 50.2$; **HRMS** (FTMS+c ESI): Calcd for C₂₃H₂₀^{78.9183}BrNO₃H⁺ [M+H⁺] 438.0699, found 438.0700; Calcd for C₂₃H₂₀^{80.9163}BrNO₃H⁺ [M+H⁺] 440.0679, found 440.0680; **IR** (neat): 2959, 2906, 2839, 1733, 1589, 1494, 1461, 1352, 1248, 1180, 1027, 865, 829, 804, 756, 689, 504 cm⁻¹.




	Retention Time	Area	% Area
1	13.550	16983310	52.43
2	35.196	15406194	47.57




	Retention Time	Area	% Area
1	13.122	46477652	96.79
2	33.433	1540077	3.21


(2a*R*,2a'*R*,5*S*,5a*R*,7*S*,7a*R*)-1-(4-Fluorophenyl)-7-(4-methoxyphenyl)-1,2,5,5a,7,7a-hexahydro-2a,5-epoxycyclopenta[*cd*]isoindol-6(2a'*H*)-one (3t)



White solid, 134 – 136 °C, 27.9 mg, 74% yield, 95% ee, >19:1 dr for the isolated product. t: 12h. $[\alpha]_D^{17} = +163.3$ (*c* 0.16, CH₂Cl₂); HPLC (Daicel chiralcel IB, $\lambda = 254$ nm, *n*-hexane/*i*-PrOH 70/30, 1.0 mL/min) $t_{R(\text{major})} = 11.02$ min, $t_{R(\text{minor})} = 26.18$ min; **¹H NMR** (400 MHz, CDCl₃) $\delta = 7.02 - 7.05$ (m, 2H), 6.90 – 6.93 (m, 2H), 6.71 – 6.75 (m, 3H), 6.49 (dd, *J* = 1.6 Hz, *J* = 6.0 Hz, 1H), 6.11 – 6.15 (m, 2H), 5.29 (d, *J* = 1.6 Hz, 1H), 4.28 (d, *J* = 6.4 Hz, *J* = 9.2 Hz, 1H), 3.92 (dd, *J* = 10.8 Hz, *J* = 87.2 Hz, 2H), 3.83 (s, 3H), 3.73 (d, *J* = 6.4 Hz, 1H), 3.10 (dd, *J* = 6.8 Hz, *J* = 9.2 Hz, 1H), 2.75 (d, *J* = 6.8 Hz, 1H); **¹³C{¹H} NMR** (101 MHz, CDCl₃) $\delta = 216.3$, 157.6 (d, *J* = 239.8 Hz, 1C), 143.4 (d, *J* = 1.5 Hz, 1C), 137.0, 136.3, 131.4, 129.9, 115.4 (d, *J* = 21.9 Hz, 1C), 114.5, 112.6 (d, *J* = 7.1 Hz, 1C), 96.2, 84.5, 66.0, 65.1, 55.3, 54.1, 52.9, 50.5; **¹⁹F{¹H} NMR** (376 MHz, CDCl₃) $\delta = -129.5$; **HRMS** (FTMS+*c* ESI): Calcd for C₂₃H₂₀FNO₃H⁺ [*M*+H⁺] 378.1500, found 378.1502; **IR** (neat): 2947, 2909, 2832, 1724, 1608, 1508, 1463, 1345, 1249, 1067, 1027, 863, 821, 755, 678, 556, 495 cm⁻¹.




	Retention Time	Area	% Area
1	10.846	20602647	51.72
2	25.188	19230578	48.28




	Retention Time	Area	% Area
1	11.022	3535257	97.36
2	26.180	96040	2.64


(2a*R*,2a¹*R*,5*S*,5a*R*,7*S*,7a*R*)-1,7-Bis(4-methoxyphenyl)-1,2,5,5a,7,7a-hexahydro-2a,5-epoxycyclopenta[*cd*]isoindol-6(2a¹*H*)-one (3u)



White solid, 115 – 117 °C, 24.1 mg, 62% yield, 82% ee, >19:1 dr for the isolated product. t: 16 h. $[\alpha]_D^{20} = +126.6$ (c 0.40, CH₂Cl₂); HPLC (Daicel chiralcel IB, $\lambda = 254$ nm, *n*-hexane/*i*-PrOH 70/30, 1.0 mL/min) $t_{R(\text{major})} = 14.30$ min, $t_{R(\text{minor})} = 30.89$ min; ¹H NMR (400 MHz, CDCl₃) $\delta = 7.05$ (d, $J = 8.8$ Hz, 2H), 6.91 (d, $J = 8.8$ Hz, 2H), 6.75 (d, $J = 5.6$ Hz, 1H), 6.63 (d, $J = 8.8$ Hz, 2H), 6.48 (dd, $J = 1.6$ Hz, $J = 5.6$ Hz, 1H), 6.17 (d, $J = 8.8$ Hz, 2H), 5.29 (d, $J = 1.2$ Hz, 1H), 4.27 (dd, $J = 6.0$ Hz, $J = 9.2$ Hz, 1H), 3.92 (dd, $J = 10.8$ Hz, $J = 91.2$ Hz, 2H), 3.84 (s, 3H), 3.74 (d, $J = 6.0$ Hz, 1H), 3.68 (s, 3H), 3.08 (dd, $J = 6.8$ Hz, $J = 9.2$ Hz, 1H), 2.74 (d, $J = 6.8$ Hz, 1H); ¹³C{¹H} NMR (101 MHz, CDCl₃) $\delta = 216.7$, 158.7, 151.3, 141.6, 137.1, 136.2, 131.5, 129.9, 114.8, 114.5, 112.8, 96.3, 84.5, 66.1, 65.4, 55.8, 55.3, 54.2, 52.9, 50.5; HRMS (FTMS+c ESI): Calcd for C₂₄H₂₃NO₄H⁺ [M+H⁺] 390.1700, found 390.1702; IR (neat): 2991, 2934, 2905, 2833, 1726, 1705, 1610, 1509, 1461, 1346, 1240, 1177, 1133, 1029, 815, 789, 674, 521 cm⁻¹.




	Retention Time	Area	% Area
1	14.330	6161404	50.96
2	31.132	5928961	49.04




	Retention Time	Area	% Area
1	14.296	40501799	91.20
2	30.893	3908759	8.80


(2a*R*,2a¹*R*,5*S*,5a*R*,7*S*,7a*R*)-7-(4-Methoxyphenyl)-1-(p-tolyl)-1,2,5,5a,7,7a-hexahydro-2a,5-epoxycyclopenta[*cd*]isoindol-6(2a¹*H*)-one (3v)



White solid, 115 – 117 °C, 29.8 mg, 80% yield, 92% ee, >19:1 dr for the isolated product. t: 16 h. $[\alpha]^{17}_D = +156.7$ (c 0.42, CH₂Cl₂); HPLC (Daicel chiralcel IB, $\lambda = 254$ nm, *n*-hexane/*i*-PrOH 70/30, 1.0 mL/min) $t_{R(\text{major})} = 10.44$ min, $t_{R(\text{minor})} = 23.81$ min; ¹H NMR (400 MHz, CDCl₃) $\delta = 7.05$ (d, $J = 8.4$ Hz, 2H), 6.91 (d, $J = 8.4$ Hz, 2H), 6.85 (d, $J = 8.4$ Hz, 2H), 6.75 (d, $J = 6.0$ Hz, 1H), 6.48 (dd, $J = 1.6$ Hz, $J = 6.0$ Hz, 1H), 6.15 (d, $J = 8.4$ Hz, 2H), 5.29 (d, $J = 1.2$ Hz, 1H), 4.31 (dd, $J = 6.0$ Hz, $J = 9.2$ Hz, 1H), 3.94 (dd, $J = 10.8$ Hz, $J = 93.2$ Hz, 2H), 3.84 (s, 3H), 3.74 (d, $J = 6.0$ Hz, 1H), 3.07 (dd, $J = 6.8$ Hz, $J = 9.2$ Hz, 1H), 2.74 (d, $J = 6.8$ Hz, 1H), 2.17 (s, 3H); ¹³C{¹H} NMR (101 MHz, CDCl₃) $\delta = 216.6$, 158.7, 144.8, 137.2, 136.2, 131.6, 129.9, 129.6, 125.6, 114.4, 112.2, 96.2, 84.5, 65.8, 65.3, 55.3, 54.2, 52.8, 50.2, 20.1; HRMS (FTMS+c ESI): Calcd for C₂₄H₂₃NO₃H⁺ [M+H⁺] 374.1751, found 374.1761; IR (neat): 2912, 2839, 1726, 1612, 1513, 1460, 1346, 1135, 1068, 1030, 862, 806, 762, 680 cm⁻¹.




	Retention Time	Area	% Area
1	10.163	23245124	53.85
2	22.758	19921885	46.15




	Retention Time	Area	% Area
1	10.435	33087397	95.89
2	23.809	1417600	4.11


(2a*R*,2a'*R*,5*S*,5a*R*,7*S*,7a*R*)-1-(4-(Tert-butyl)phenyl)-7-(4-methoxyphenyl)-1,2,5,5a,7,7a-hexahydro-2a,5-epoxycyclopenta[*cd*]isoindol-6(2a'*H*)-one (3w)



White solid, 132- 134 °C, 30.7 mg, 74% yield, 91% ee, >19:1 dr for the isolated product. t: 16 h. $[\alpha]_D^{19} = +137.3$ (c 0.24, CH₂Cl₂); HPLC (Daicel chiralcel IB, $\lambda = 254$ nm, *n*-hexane/*i*-PrOH 70/30, 1.0 mL/min) $t_{R(\text{major})} = 8.97$ min, $t_{R(\text{minor})} = 21.19$ min; **¹H NMR** (400 MHz, CDCl₃) $\delta = 7.06 - 7.09$ (m, 4H), 6.93 (d, $J = 8.8$ Hz, 2H), 6.75 (d, $J = 5.6$ Hz, 1H), 6.48 (dd, $J = 5.6$ Hz, $J = 1.6$ Hz, $J = 6.0$ Hz, 1H), 6.22 (d, $J = 8.8$ Hz, 2H), 5.29 (d, $J = 1.2$ Hz, 1H), 4.32 (dd, $J = 6.0$ Hz, $J = 9.2$ Hz, 1H), 3.95 (dd, $J = 11.2$ Hz, $J = 88.8$ Hz, 2H), 3.85 (s, 3H), 3.75 (s, $J = 6.0$ Hz, 1H), 3.06 (dd, $J = 6.8$ Hz, $J = 8.8$ Hz, 1H), 2.75 (d, $J = 6.4$ Hz, 1H), 1.23 (s, 9H); **¹³C{¹H} NMR** (101 MHz, CDCl₃) $\delta = 216.6, 158.7, 144.8, 139.3, 137.2, 136.2, 131.6, 129.9, 125.9, 114.5, 111.8, 96.2, 84.6, 65.9, 65.2, 55.3, 54.2, 52.9, 50.2, 33.7, 31.5$; **HRMS** (FTMS+c ESI): Calcd for C₂₇H₂₉NO₃H⁺ [M+H⁺] 416.2220, found 416.2207; **IR** (neat): 2957, 2837, 1729, 1610, 1515, 1461, 1343, 1254, 1134, 1032, 862, 824, 770, 686, 589, 554 cm⁻¹.




	Retention Time	Area	% Area
1	9.046	5386736	50.62
2	20.724	5254209	49.38




	Retention Time	Area	% Area
1	8.971	37807973	95.58
2	21.193	1746995	4.42


(2a*R*,2a'*R*,5*S*,5a*R*,7*S*,7a*R*)-7-(4-Methoxyphenyl)-1-(naphthalen-2-yl)-1,2,5,5a,7,7a-hexahydro-2a,5-epoxycyclopenta[*cd*]isoindol-6(2a'*H*)-one (3x)



White solid, 125 – 127 °C, 22.9 mg, 56% yield, 91% ee, >19:1 dr for the isolated product. t: 21 h. $[\alpha]_D^{19} = +190.2$ (c 0.50, CH₂Cl₂); HPLC (Daicel chiralcel IB, $\lambda = 254$ nm, *n*-hexane/*i*-PrOH 70/30, 1.0 mL/min) $t_{R(\text{major})} = 20.11$ min, $t_{R(\text{minor})} = 37.13$ min; ¹H NMR (400 MHz, CDCl₃) $\delta = 7.60$ (d, $J = 8.0$ Hz, 1H), 7.50 (d, $J = 8.8$ Hz, 1H), 7.22 – 7.29 (m, 2H), 7.14 – 7.16 (m, 1H), 7.08 – 7.12 (m, 2H), 6.96 (d, $J = 8.4$ Hz, 2H), 6.77 (d, $J = 5.6$ Hz, 1H), 6.62 (dd, $J = 2.4$ Hz, $J = 8.8$ Hz, 1H), 6.51 (dd, $J = 1.6$ Hz, $J = 6.0$ Hz, 1H), 6.14 (d, $J = 2.0$ Hz, 1H), 5.32 (d, $J = 1.2$ Hz, 1H), 4.47 (dd, $J = 6.4$ Hz, $J = 9.2$ Hz, 1H), 4.09 (dd, $J = 11.2$ Hz, $J = 86.8$ Hz, 2H), 3.87 (s, 3H), 3.82 (s, 1H), 3.13 (dd, $J = 6.8$ Hz, $J = 9.2$ Hz, 1H), 2.79 (d, $J = 6.4$ Hz, 1H); ¹³C{¹H} NMR (101 MHz, CDCl₃) $\delta = 216.4, 158.9, 144.6, 137.1, 136.3, 134.7, 131.7, 130.1, 128.8, 127.3, 126.6, 126.2, 126.0, 121.8, 115.5, 114.5, 106.4, 96.2, 84.5, 65.9, 65.1, 55.4, 54.2, 52.8, 50.3$; HRMS (FTMS+c ESI): Calcd for C₂₇H₂₃NO₃H⁺ [M+H⁺] 410.1751, found 410.1758; IR (neat): 2954, 2913, 2839, 1726, 1625, 1600, 1509, 1463, 1391, 1366, 1246, 1143, 1031, 861, 828, 808, 741, 678, 469 cm⁻¹.




	Retention Time	Area	% Area
1	21.536	37491783	50.54
2	36.342	36687280	49.46




	Retention Time	Area	% Area
1	20.112	125922071	95.72
2	37.126	5628920	4.28


(2a*R*,2a¹*R*,5*S*,5a*R*,7*S*,7a*R*)-7-(4-Methoxyphenyl)-5-methyl-1-phenyl-1,2,5,5a,7,7a-hexahydro-2a,5-epoxycyclopenta[*cd*]isoindol-6(2a¹*H*)-one (3y)



White solid, 112 – 114 °C, 33.6 mg, 90% yield, 89% ee, >19:1 dr for the isolated product. t: 20 h. $[\alpha]^{20}_D = +190.7$ (c 0.30, CH₂Cl₂); HPLC (Daicel chiralcel IB, $\lambda = 254$ nm, *n*-hexane/*i*-PrOH 70/30, 1.0 mL/min) $t_{R(\text{major})} = 7.91$ min, $t_{R(\text{minor})} = 13.23$ min; **¹H NMR** (400 MHz, CDCl₃) $\delta = 7.00 - 7.04$ (m, 4H), 6.90 (d, $J = 8.4$ Hz, 2H), 6.73 (d, $J = 5.6$ Hz, 1H), 6.60 (t, $J = 6.8$ Hz, 1H), 6.31 (d, $J = 5.6$ Hz, 1H), 6.19 (d, $J = 8.4$ Hz, 2H), 4.28 (dd, $J = 6.8$ Hz, $J = 9.2$ Hz, 1H), 3.92 (dd, $J = 10.8$ Hz, $J = 93.2$ Hz, 2H), 3.84 (s, 3H), 3.16 (dd, $J = 6.8$ Hz, $J = 9.2$ Hz, 1H), 2.60 (d, $J = 6.4$ Hz, 1H), 1.67 (s, 3H); **¹³C{¹H} NMR** (101 MHz, CDCl₃) $\delta = 215.1, 158.7, 147.0, 140.1, 137.3, 131.5, 130.2, 129.0, 116.5, 114.4, 112.2, 95.4, 90.8, 65.3, 65.1, 56.9, 55.5, 55.3, 50.6, 15.7$; **HRMS** (FTMS+c ESI): Calcd for C₂₄H₂₃NO₃H⁺ [M+H⁺] 374.1751, found 374.1753; **IR** (neat): 3054, 3040, 2974, 2910, 2838, 1723, 1597, 1506, 1462, 1350, 1250, 1181, 1140, 1030, 867, 836, 743, 689, 587, 549, 507 cm⁻¹.




	Retention Time	Area	% Area
1	8.397	4901449	50.98
2	13.012	4713826	49.02




	Retention Time	Area	% Area
1	7.911	42381827	94.58
2	13.228	2429912	5.42

(4*R*,5*S*)-5-(4-Methoxyphenyl)-4-(phenyl(thiophen-2-ylmethyl)amino)cyclopent-2-en-1-one
(4bn)




4bn

White solid, 120 – 122 °C, 35.6 mg, 95% yield, 89% ee, >19:1 dr for the isolated product. t: 25 h. $[\alpha]_D^{19} = -156.6$ (*c* 0.49, CH₂Cl₂); HPLC (Daicel chiralcel IB, $\lambda = 254$ nm, *n*-hexane/*i*-PrOH 70/30, 1.0 mL/min) $t_{R(\text{major})} = 11.25$ min, $t_{R(\text{minor})} = 13.87$ min; **¹H NMR** (400 MHz, CDCl₃) $\delta = 7.76$ (dd, $J = 2.4$ Hz, $J = 6.0$ Hz, 1H), 7.19 – 7.21 (m, 1H), 7.13 – 7.17 (m, 2H), 7.00 – 7.03 (m, 2H), 6.93 – 6.95 (m, 1H), 6.86 – 6.89 (m, 3H), 6.79 – 6.82 (m, 1H), 6.74 – 6.76 (m, 2H), 6.42 (dd, $J = 2.0$ Hz, $J = 5.6$ Hz, 1H), 5.11 (q, $J = 2.4$ Hz, 1H), 4.57 (dd, $J = 16.8$ Hz, $J = 5.2$ Hz, $J = 59.2$ Hz, 2H), 3.81 (s, 3H), 3.54 (d, $J = 3.2$ Hz, 1H); **¹³C{¹H} NMR** (101 MHz, CDCl₃) $\delta = 206.6, 162.7, 158.8, 147.9, 143.6, 135.1, 130.2, 129.2, 129.2, 126.9, 124.7, 124.5, 119.4, 115.8, 114.5, 69.2, 56.2, 55.2, 47.6$; **HRMS** (FTMS+*c* ESI): Calcd for C₂₃H₂₁NO₂SH⁺ [M+H⁺] 376.1366, found 376.1366. **IR** (neat): 2925, 2830, 1700, 1597, 1505, 1255, 1172, 1032, 805, 749, 691, 607, 515 cm⁻¹.




	Retention Time	Area	% Area
1	10.953	11836757	50.07
2	13.266	11802425	49.93




	Retention Time	Area	% Area
1	11.248	12263542	94.48
2	13.870	717042	5.52

(4*R*,5*S*)-4-((3-(Furan-2-yl)propyl)(phenyl)amino)-5-(4-methoxyphenyl)cyclopent-2-en-1-one (4bo)




4bo

Yellow oil, 32.0 mg, 83% yield, 43% ee, >19:1 dr for the isolated product. t : 16 h. $[\alpha]_D^{17} = -70.1$ (c 0.32, CH_2Cl_2); HPLC (Daicel chiralcel IB, $\lambda = 254$ nm, n -hexane/ i -PrOH 70/30, 1.0 mL/min) $t_{R(\text{major})} = 8.46$ min, $t_{R(\text{minor})} = 10.39$ min; $^1\text{H NMR}$ (400 MHz, CDCl_3) $\delta = 7.70$ (dd, $J = 2.0$ Hz, $J = 5.6$ Hz, 1H), 7.31 (d, $J = 1.2$ Hz, 1H), 7.13 (dd, $J = 7.6$ Hz, $J = 8.4$ Hz, 2H), 7.00 (d, $J = 8.4$ Hz, 2H), 6.86 (d, $J = 8.4$ Hz, 2H), 6.76 (t, $J = 7.2$ Hz, 1H), 6.64 (d, $J = 8.0$ Hz, 2H), 6.40 (dd, $J = 2.0$ Hz, $J = 5.6$ Hz, 1H), 6.29 (dd, $J = 2.0$ Hz, $J = 2.8$ Hz, 1H), 5.98 (d, $J = 2.8$ Hz, 1H), 4.94 (d, $J = 2.4$ Hz, 1H), 3.97 (s, 3H), 3.46 (d, $J = 2.8$ Hz, 1H), 3.24 – 3.30 (m, 1H), 3.10 – 3.23 (m, 1H), 2.65 (t, $J = 7.2$ Hz, 2H), 1.83 – 1.99 (m, 2H); $^{13}\text{C}\{^1\text{H}\}$ NMR (101 MHz, CDCl_3) $\delta = 206.7$, 163.1, 158.7, 154.9, 147.7, 141.0, 134.8, 130.2, 129.2, 129.2, 118.8, 115.7, 114.4, 110.2, 105.3, 70.6, 56.4, 55.2, 46.4, 27.1, 25.2; HRMS (FTMS+c ESI): Calcd for $\text{C}_{25}\text{H}_{25}\text{NO}_3\text{H}^+$ $[\text{M}+\text{H}^+]$ 388.1907, found 388.1898. IR (neat): 2952, 2360, 1710, 1598, 1508, 1251, 1178, 750 cm^{-1} .




	Retention Time	Area	% Area
1	8.633	51999170	47.32
2	10.611	57897191	52.68




	Retention Time	Area	% Area
1	8.464	34007595	71.53
2	10.390	13538578	28.47

(4*R*,5*S*)-4-(Benzyl(phenyl)amino)-5-(4-methoxyphenyl)cyclopent-2-en-1-one (4bp)




4bp

Yellow oil, 26.9 mg, 73% yield, 50% ee, >19:1 dr for the isolated product. t: 16 h. $[\alpha]_D^{20} = -74.5$ (*c* 0.42, CH₂Cl₂); HPLC (Daicel chiralcel IB, $\lambda = 254$ nm, *n*-hexane/*i*-PrOH 90/10, 1.0 mL/min) $t_{R(\text{minor})} = 23.58$ min, $t_{R(\text{major})} = 25.03$ min; **¹H NMR** (400 MHz, CDCl₃) $\delta = 7.69$ (dd, *J* = 2.0 Hz, *J* = 6.0 Hz, 2H), 7.32 – 7.35 (m, 2H), 7.25 – 7.28 (m, 2H), 7.11 (dd, *J* = 7.6 Hz, *J* = 8.4 Hz, 2H), 7.00 (d, *J* = 8.4 Hz, 2H), 6.88 (d, *J* = 8.4 Hz, 2H), 6.75 (t, *J* = 7.2 Hz, 1H), 6.65 (d, *J* = 8.4 Hz, 2H), 6.41 (dd, *J* = 2.0 Hz, *J* = 5.6 Hz, 1H), 5.23 (d, *J* = 2.0 Hz, 1H), 4.44 (dd, *J* = 17.2 Hz, *J* = 51.6 Hz, 2H), 3.81 (s, 3H), 3.49 (d, *J* = 4.0 Hz, 1H); **¹³C{¹H} NMR** (101 MHz, CDCl₃) $\delta = 206.7, 162.5, 158.8, 148.6, 139.1, 135.3, 130.2, 129.2, 129.2, 128.7, 127.1, 126.3, 118.5, 114.5, 114.5, 68.7, 56.4, 55.3, 51.1$; **HRMS** (FTMS+c ESI): Calcd for C₂₅H₂₃NO₂H⁺ [M+H⁺] 370.1801, found 370.1792; **IR** (neat): 3032, 2931, 2361, 1710, 1599, 1508, 1251, 1032, 751, 695 cm⁻¹.




	Retention Time	Area	% Area
1	23.448	42286656	49.30
2	25.181	43493935	50.70




	Retention Time	Area	% Area
1	23.584	17473894	25.13
2	25.031	52063157	74.87

(4*R*,5*S*)-5-(4-Methoxyphenyl)-4-(methyl(phenyl)amino)cyclopent-2-en-1-one (4bq)




4bq

Yellow oil, 26.1 mg, 89% yield, 56% ee, >19:1 dr for the isolated product. t: 16 h. $[\alpha]_D^{19} = -80.5$ (*c* 0.46, CH₂Cl₂); HPLC (Daicel chiralcel IB, $\lambda = 254$ nm, *n*-hexane/*i*-PrOH 70/30, 1.0 mL/min) $t_{R(\text{major})} = 9.60$ min, $t_{R(\text{minor})} = 10.61$ min; **¹H NMR** (400 MHz, CDCl₃) $\delta = 7.70$ (dd, *J* = 2.4 Hz, *J* = 5.6 Hz, 1H), 7.12 – 7.16 (m, 2H), 7.00 (d, *J* = 8.8 Hz, 2H), 6.85 (d, *J* = 8.8 Hz, 2H), 6.74 (t, *J* = 7.2 Hz, 1H), 6.65 (d, *J* = 8.0 Hz, 2H), 6.46 (dd, *J* = 2.0 Hz, *J* = 5.6 Hz, 1H), 5.08 (d, *J* = 2.0 Hz, 1H), 3.79 (s, 3H), 3.48 (d, *J* = 2.8 Hz, 1H), 2.85 (s, 3H); **¹³C{¹H} NMR** (101 MHz, CDCl₃) $\delta = 206.8, 163.1, 158.7, 149.2, 135.0, 130.2, 129.1, 118.3, 114.4, 114.3, 69.8, 55.4, 55.2, 33.2$; **HRMS** (FTMS+c ESI): Calcd for C₁₉H₁₉NO₂H⁺ [M+H⁺] 294.1489, found 294.1483; **IR** (neat): 2932, 2362, 1710, 1599, 1508, 1376, 1250, 1179, 1108, 1033, 824, 752, 693 cm⁻¹.




	Retention Time	Area	% Area
1	9.676	44268959	50.84
2	10.590	42810188	49.16



	Retention Time	Area	% Area
1	9.600	39152684	78.14
2	10.607	10954539	21.86


8. Product derivatizations




(2a*R*,2a¹*R*,5*S*,5a*R*,6*S*,7*S*,7a*R*)-6-Allyl-7-(4-methoxyphenyl)-1-phenyl-1,2,2a¹,5,5a,6,7,7a-octahydro-2a,5-epoxycyclopenta[*cd*]isoindol-6-ol (**5**)

At $-20\text{ }^{\circ}\text{C}$, a solution of allylmagnesium bromide (0.30 mL, 0.30 mmol, 1.0 M in ether) was slowly added to a solution of compound **3b** (35.9 mg, 0.10 mmol, 95% ee) in THF (1 mL). The reaction was allowed to warm up to rt. The progress was monitored by thin layer chromatography. Upon completion, a saturated aqueous solution of NH_4Cl (1 mL) was added. The layers were separated, and the aqueous layer was extracted with EtOAc (5 mL $\times$ 3). The combined organic layers were dried over anhydrous Na_2SO_4 and concentrated. The residue was subjected to column chromatography on silica gel and eluted with EtOAc/petroleum ether (1:3, v/v) to give the product **5** as a white solid (91% yield, > 19:1 dr, 94% ee).


White solid, 97 – 99 $^{\circ}\text{C}$, 36.3 mg, 91% yield, 94% ee, >19:1 dr for the isolated product. t: 6 h. $[\alpha]_{\text{D}}^{19} = -92.4$ (c 0.33, CH_2Cl_2); HPLC (Daicel chiralcel IB, $\lambda = 254\text{ nm}$, n -hexane/*i*-PrOH 70/30, 1.0 mL/min) $t_{\text{R}}(\text{minor}) = 6.52\text{ min}$, $t_{\text{R}}(\text{major}) = 7.15\text{ min}$; $^1\text{H NMR}$ (400 MHz, CDCl_3) $\delta = 7.21$ (d, $J = 8.8\text{ Hz}$, 2H), 6.98 (t, $J = 8.0\text{ Hz}$, 2H), 6.73 (d, $J = 8.8\text{ Hz}$, 2H), 6.62 (d, $J = 6.0\text{ Hz}$, 1H), 6.56 (t, $J = 7.2\text{ Hz}$, 1H), 6.48 (dd, $J = 1.6\text{ Hz}$, $J = 5.6\text{ Hz}$, 1H), 6.36 (d, $J = 8.4\text{ Hz}$, 2H), 5.81 – 5.92 (m, 1H), 5.35 (d, $J = 1.2\text{ Hz}$, 1H), 5.17 (d, $J = 10.4\text{ Hz}$, 1H), 5.07 (d, $J = 17.2\text{ Hz}$, 1H), 4.23 (t, $J = 8.8\text{ Hz}$, 1H), 3.98 (d, $J = 11.2\text{ Hz}$, 1H), 3.72 – 3.75 (m, 5H), 2.72 – 2.76 (m, 1H), 2.34 (d, $J = 6.8\text{ Hz}$, 1H), 2.05 – 2.16 (m, 3H); $^{13}\text{C}\{^1\text{H}\}\text{NMR}$ (101 MHz, CDCl_3) $\delta = 158.6, 147.9, 137.1, 136.2, 134.0, 131.1, 129.8, 128.8, 119.2, 116.1, 113.6, 112.4, 94.2, 82.2, 81.3, 64.4, 64.0, 55.2, 54.2, 51.1, 48.5, 43.4$; **HRMS** (FTMS+c ESI): Calcd for $\text{C}_{26}\text{H}_{27}\text{NO}_3\text{H}^+$ $[\text{M}+\text{H}^+]$ 402.2064, found 402.2061; **IR** (neat): 3463, 2954, 2905, 2836, 1638, 1505, 1343, 1246, 1067, 1031, 995, 869, 835, 750, 690, 553 cm^{-1} .



	Retention Time	Area	% Area
1	6.140	2059371	49.31
2	6.812	2116720	50.69




	Retention Time	Area	% Area
--	----------------	------	--------




(2aR,2a¹R,5S,5aR,7S,7aR)-7-(4-Methoxyphenyl)-1-phenyloctahydro-2a,5-epoxycyclopenta[cd]isoindol-6(2a¹H)-one (6)

At room temperature, a flask was charged with a solution of the compound **3b** (35.9 mg, 0.10 mmol, 95% ee) in EtOAc (4 mL), Pd/C (10.0 mg) was added in one portion to the above solution. The flask was evacuated and refilled with H₂ with a balloon. The reaction mixture was stirred under H₂ atmosphere for 5 h. Then the reaction mixture was filtered through a pad of celite. The filtrate was concentrated in vacuo and the residue was subjected to column chromatography on silica gel and eluted with EtOAc/petroleum ether (1:3, v/v) to give the product **6** as a white solid (90% yield, > 19:1 dr, 95% ee).


White solid, 168 – 170 °C, 32.5 mg, 90% yield, 95% ee, >19:1 dr for the isolated product. t: 5 h. $[\alpha]_D^{20} = +128.7$ (c 0.42, CH₂Cl₂); HPLC (Daicel chiralcel IB, $\lambda = 254$ nm, *n*-hexane/*i*-PrOH 70/30, 1.0 mL/min) $t_{R(\text{major})} = 9.92$ min, $t_{R(\text{minor})} = 32.10$ min; ¹H NMR (400 MHz, CDCl₃) $\delta = 7.01 - 7.05$ (m, 4H), 6.89 – 6.91 (d, $J = 8.8$ Hz, 2H), 6.62 (d, $J = 7.2$ Hz, 1H), 6.24 (d, $J = 8.0$ Hz, 2H), 4.83 (d, $J = 5.2$ Hz, 1H), 4.32 (dd, $J = 6.0$ Hz, $J = 9.2$ Hz, 1H), 3.83 (s, 3H), 3.80 (dd, $J = 10.8$ Hz, $J = 157.2$ Hz, 2H), 3.53 (d, $J = 6.0$ Hz, 1H), 3.09 – 3.13 (m, 1H), 2.87 (d, $J = 7.2$ Hz, 1H), 1.97 – 2.10 (m, 2H), 1.84 – 1.89 (m, 1H), 1.72 – 1.78 (m, 1H); ¹³C{¹H} NMR (101 MHz, CDCl₃) $\delta = 218.4, 158.7, 147.0, 131.5, 129.8, 129.0, 116.4, 114.5, 112.3, 93.7, 82.0, 68.1, 64.2, 59.1, 55.3, 51.7, 51.3, 29.2, 29.1$; HRMS (FTMS+c ESI): Calcd for C₂₃H₂₃NO₃H⁺ [M+H⁺] 362.1751, found 362.1759; IR (neat): 2950, 2915, 2832, 1731, 1594, 1504, 1347, 1246, 1171, 1131, 1030, 812, 750, 690, 517 cm⁻¹.



	Retention Time	Area	% Area
1	9.951	7765255	50.47
2	31.118	7620598	49.53




	Retention Time	Area	% Area
1	9.918	42481673	97.41
2	32.102	1127975	2.59




(2aR,2a¹R,5S,5aS,6R,7S,7aS)-7-(4-Methoxyphenyl)-1-phenyl-1,2,2a,5,5a,6,7,7a-octahydro-2a,5-epoxycyclopenta[cd]isoindol-6-ol (7)

At room temperature, to a flask charged with a solution of the compound **3b** (117.2 mg, 0.33 mmol, 95% ee) in MeOH (4 mL) was added NaBH₄ (12.4 mg) in one portion. The resultant reaction mixture was stirred at room temperature. After completion of the reaction, methanol was removed under reduced pressure and the residue was purified by silica gel flash chromatography (ethyl acetate: petroleum ether = 1:1 to 3:1) to give the product **7** as a white solid (95% yield, > 19:1 dr, 97% ee).

White solid, 188 – 190 °C, 112.0 mg, 95% yield, 97% ee, >19:1 dr for the isolated product. t: 3 h. $[\alpha]_D^{20} = +49.1$ (*c* 0.22, CH₂Cl₂); HPLC (Daicel chiralcel IB, $\lambda = 254$ nm, *n*-hexane/*i*-PrOH 70/30, 1.0 mL/min) $t_{R(\text{major})} = 8.62$ min, $t_{R(\text{minor})} = 10.90$ min; ¹H NMR (400 MHz, CDCl₃) $\delta = 7.21$ (d, *J* = 8.4 Hz, 2H), 6.94 (t, *J* = 8.0 Hz, 2H), 6.84 (d, *J* = 8.4 Hz, 2H), 6.62 (d, *J* = 6.0 Hz, 1H), 6.53 (t, *J* = 7.2 Hz, 1H), 6.47 (dd, *J* = 1.2 Hz, *J* = 6.0 Hz, 1H), 6.08 (d, *J* = 8.0 Hz, 2H), 5.44 (d, *J* = 0.8 Hz, 1H), 4.42 – 4.48 (m, 1H), 4.01 (t, *J* = 8.0 Hz, 1H), 3.83 (dd, *J* = 11.2 Hz, *J* = 88.4 Hz, 2H), 3.81 (s, 3H), 3.37 (dd, *J* = 8.0 Hz, *J* = 10.4 Hz, 1H), 2.71 (dd, *J* = 6.8 Hz, *J* = 8.4 Hz, 1H), 2.42 (t, *J* = 7.2 Hz, 1H), 1.94 (d, *J* = 5.6 Hz, 1H); ¹³C{¹H} NMR (101 MHz, CDCl₃) $\delta = 158.7, 147.4, 136.9, 135.9, 134.9, 129.0, 128.8, 115.8, 114.5, 111.9, 94.4, 81.0, 79.9, 66.8, 60.6, 55.3, 54.1, 50.4, 45.9$; HRMS (FTMS+c ESI): Calcd for C₂₃H₂₃NO₃H⁺ [M+H⁺] 362.1751, found 362.1747; IR (neat): 3336, 2954, 2902, 2837, 1597, 1505, 1461, 1344, 1245, 1079, 1027, 866, 834, 808, 749, 688, 548 cm⁻¹.




	Retention Time	Area	% Area
1	8.766	948451	47.64
2	10.782	1042575	52.36



	Retention Time	Area	% Area
1	8.617	24162182	98.60
2	10.901	343657	1.40

9. X-ray structure of 3m



Single crystal of **3m** was obtained from the mixed solvents of petroleum ether and dichloromethane. The absolute configuration was shown above. CCDC 1971783 (**3m**) was assigned to be (2aR,2a¹R,5S,5aR,7S,7aR) respectively. These data can be obtained free from the Cambridge Crystallographic Data Centre via www.ccdc.cam.ac.uk/data_request/cif.

Crystal data and structure refinement for.

Empirical formula	C ₂₂ H ₁₈ BrNO ₂
Formula weigh	408.28
Temperature/K	300(2)
Crystal system	Orthorhombic
Space group	P2 ₁ 2 ₁ 2 ₁
a/Å	5.8675(3)
b/Å	12.4208(7)
c/Å	24.4967(14)
α/°	90
β/°	90
γ/°	90
Volume/Å ³	1785.30(17)
Z	4
ρ _{calc} /cm ³	1.519
μ/mm ⁻¹	2.319
F(000)	832.0
Crystal size/mm ³	
Radiation	MoKα (λ = 0.71073)
2θ range for data collection/°	5.97 to 49.454
Index ranges	-6 ≤ h ≤ 6, -14 ≤ k ≤ 14, -28 ≤ l ≤ 28
Reflections collected	9416
Independent reflections	2964 [R _{int} = 0.0269, R _{sigma} = 0.0486]
Data/restraints/parameters	2964/0/235
Goodness-of-fit on F ²	1.040
Final R indexes [I ≥ 2σ (I)]	R ₁ = 0.0300, wR ₂ = 0.0660

Final R indexes [all data]	$R_1 = 0.0374$, $wR_2 = 0.0705$
Largest diff. peak/hole / e Å	0.49/-0.52
Flack parameter	0.002(5)


10. Control experiments

As described in the previous literature^[2], it was found that there was always minor isomers related to the corresponding uncyclized intermediates according to the spectra of the desired products. We rationalized that there is an equilibrium between uncyclized intermediate **4** and the [4+2] cycloaddition product **3**. To confirmed this assumption, several control experiments were carried out.

Firstly, we recrystallized the product **3a** and analyzed it by ¹H NMR. After preparing the sample, we measured the ¹H NMR spectrum of crystals in CDCl₃. Pure ¹H NMR spectra of **3a** was obtained (a). However, rescan the sample with 0.5-2 hours, new peaks related to the uncyclized intermediate **4a** was detected. The ratio between **4a** and **3a** increased from <1:19, to 1:7.1, 1:6 and 1:6 after 0.5 h, 1 h, and 2 h.

Secondly, the ratio of [4+2] cycloaddition product **3a** to uncyclized intermediate **4a** changed when the ¹H NMR spectra was detected with *d*-DMSO as the solvent. It was found that the ratio between the product **3a** and the uncyclized intermediate **4a** decreased to 5.3:1 in *d*-DMSO, indicating a reversible [4+2] cycloaddition process.

It was interesting to found that hydrogenation of the mixture of the product **3a/4a** (6:1) afforded pure product **8** in 99% yield, which again indicated that the exist of the dynamic equilibrium between the product **3a** and the uncyclized intermediate **4a** was responsible for the impurity in our spectra of final products.










Figure S1. Different time ^1H NMR spectra of the product **3a** after recrystallized. From top to bottom, newly recrystallized product **3a**, the ratio of product **3a** to **4a** changed: 19:1 (a); 7.1:1 (b/0.5 h); 6:1 (c/1 h); and 6:1 (d/2 h).

In *d*-DMSO, the ratio of product **3a** to uncyclized intermediate **4a** is 5.3:1.







Product 8











11. Copies of NMR spectra







































































































































12. Copies of CD spectra







































13. References

- [1] B. Martin-Matute, C. Nevado, D. J. Cardenas and A. M. Echavarren, *J. Am. Chem. Soc.*, 2003, **125**, 5757.
- [2] S. Gouse, N. R. Reddy and S. Baskaran, *Org. Lett.*, 2019, **21**, 3822.
- [3] R. Savka and H. Plenio, *Eur. J. Inorg. Chem.* 2014, 6246.
- [4] (a) X. H. Liu, L. L. Lin and X. M. Feng, *Acc. Chem. Res.*, 2011, **44**, 574; (b) X. H. Liu, L. L. Lin and X. M. Feng, *Org. Chem. Front.*, 2014, **1**, 298.